



Cochrane
Library

Cochrane Database of Systematic Reviews

Mepolizumab versus placebo for asthma (Review)

Powell C, Milan SJ, Dwan K, Bax L, Walters N

Powell C, Milan SJ, Dwan K, Bax L, Walters N.

Mepolizumab versus placebo for asthma.

Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD010834.

DOI: 10.1002/14651858.CD010834.pub2.

www.cochranelibrary.com

Mepolizumab versus placebo for asthma (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	3
BACKGROUND	6
OBJECTIVES	6
METHODS	6
RESULTS	9
Figure 1.	10
Figure 2.	11
Figure 3.	12
ADDITIONAL SUMMARY OF FINDINGS	16
DISCUSSION	19
AUTHORS' CONCLUSIONS	20
ACKNOWLEDGEMENTS	20
REFERENCES	20
CHARACTERISTICS OF STUDIES	30
DATA AND ANALYSES	52
Analysis 1.1. Comparison 1 IV Mepolizumab versus placebo, Outcome 1 Health-related quality of life (AQLQ).	54
Analysis 1.2. Comparison 1 IV Mepolizumab versus placebo, Outcome 2 Health-related quality of life (SGRQ).	55
Analysis 1.3. Comparison 1 IV Mepolizumab versus placebo, Outcome 3 Rate of clinically significant exacerbations.	56
Analysis 1.4. Comparison 1 IV Mepolizumab versus placebo, Outcome 4 Rate of exacerbations requiring admission.	57
Analysis 1.5. Comparison 1 IV Mepolizumab versus placebo, Outcome 5 Rate of exacerbations requiring ED or admission.	58
Analysis 1.6. Comparison 1 IV Mepolizumab versus placebo, Outcome 6 People with one or more exacerbations.	59
Analysis 1.7. Comparison 1 IV Mepolizumab versus placebo, Outcome 7 Serious adverse events.	60
Analysis 1.8. Comparison 1 IV Mepolizumab versus placebo, Outcome 8 FEV1 (litres).	61
Analysis 1.9. Comparison 1 IV Mepolizumab versus placebo, Outcome 9 PEFr (L/min).	62
Analysis 1.10. Comparison 1 IV Mepolizumab versus placebo, Outcome 10 Post bronchodilator FEV1 (L).	63
Analysis 1.11. Comparison 1 IV Mepolizumab versus placebo, Outcome 11 Percentage predicted FEV1 after bronchodilation.	63
Analysis 1.12. Comparison 1 IV Mepolizumab versus placebo, Outcome 12 Pre-bronchodilator FEV1 (L) at week 32.	64
Analysis 1.13. Comparison 1 IV Mepolizumab versus placebo, Outcome 13 Pre-bronchodilator FEV1 (mL) at week 52.	64
Analysis 1.14. Comparison 1 IV Mepolizumab versus placebo, Outcome 14 Late asthmatic reaction (maximum % fall in FEV1).	65
Analysis 1.15. Comparison 1 IV Mepolizumab versus placebo, Outcome 15 Asthma symptoms.	66
Analysis 1.16. Comparison 1 IV Mepolizumab versus placebo, Outcome 16 Asthma symptoms (JACQ).	67
Analysis 2.1. Comparison 2 SC Mepolizumab versus placebo, Outcome 1 Health-related quality of life.	67
Analysis 2.2. Comparison 2 SC Mepolizumab versus placebo, Outcome 2 Rate of exacerbations requiring admission.	68
Analysis 2.3. Comparison 2 SC Mepolizumab versus placebo, Outcome 3 Rate of exacerbations requiring ED or admission.	68
Analysis 2.4. Comparison 2 SC Mepolizumab versus placebo, Outcome 4 Rate of clinically significant exacerbations.	69
Analysis 2.5. Comparison 2 SC Mepolizumab versus placebo, Outcome 5 Pre bronchodilator FEV1 (litres).	69
Analysis 2.6. Comparison 2 SC Mepolizumab versus placebo, Outcome 6 Post bronchodilator FEV1 (litres).	70
Analysis 2.7. Comparison 2 SC Mepolizumab versus placebo, Outcome 7 Asthma symptoms.	70
ADDITIONAL TABLES	70
APPENDICES	76
CONTRIBUTIONS OF AUTHORS	79
DECLARATIONS OF INTEREST	79
SOURCES OF SUPPORT	79
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	79

[Intervention Review]

Mepolizumab versus placebo for asthma

Colin Powell¹, Stephen J Milan², Kerry Dwan³, Lynne Bax⁴, Nicola Walters⁵

¹Department of Child Health, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, UK. ²Lancaster Health Hub, Lancaster University, Lancaster, UK. ³Department of Biostatistics, University of Liverpool, Liverpool, UK. ⁴Lancashire Care NHS Foundation Trust, Preston, UK. ⁵Chest Unit, St George's University Hospitals NHS Foundation Trust, London, UK

Contact address: Colin Powell, Department of Child Health, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, UK. PowellC7@cardiff.ac.uk.

Editorial group: Cochrane Airways Group.

Publication status and date: New, published in Issue 7, 2015.

Review content assessed as up-to-date: 19 November 2014.

Citation: Powell C, Milan SJ, Dwan K, Bax L, Walters N. Mepolizumab versus placebo for asthma. *Cochrane Database of Systematic Reviews* 2015, Issue 7. Art. No.: CD010834. DOI: 10.1002/14651858.CD010834.pub2.

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation. Recent studies have suggested these agents may have a role in reducing exacerbations and improving health-related quality of life (HRQoL). There are no recommendations for the use of mepolizumab in adults or children in the recent update of the BTS/SIGN guidelines ([BTS/SIGN 2014](#)).

Objectives

To compare the effects of mepolizumab with placebo on exacerbations and HRQoL in adults and children with chronic asthma.

Search methods

We searched the Cochrane Airways Group Register (CAGR) of trials, clinical trial registries, manufacturers' websites and the reference lists of included studies. Searches were conducted in November 2013 and updated in November 2014.

Selection criteria

We included randomised controlled trials comparing mepolizumab versus placebo in adults and children with asthma.

Data collection and analysis

Two authors independently extracted data and analysed outcomes using a random-effects model. We used standard methods expected by The Cochrane Collaboration.

Main results

Eight studies on 1707 participants met the inclusion criteria. Only two studies included children (over 12 years of age), but they did not report separate findings for the adolescents. Seven studies involved intravenous mepolizumab alone; one included a subcutaneous arm. There was heterogeneity in the severity and clinical pattern of asthma among the participants in the eight studies, varying from mild to moderate atopic asthma, to persistent asthma and eosinophilic asthma with recurrent exacerbations. Selection bias was a concern in several of the studies included in this review.

Four trials compared intravenous mepolizumab to placebo in relation to HRQoL. Two studies measured scores from the Asthma Quality of Life Questionnaire (AQLQ), which showed a non-significant difference between mepolizumab and placebo (mean difference (MD) 0.21, 95% confidence interval (CI) – 0.01 to 0.44; participants = 682), in the direction favouring mepolizumab. The third study used the St. George's Respiratory Questionnaire (SGRQ) and found a significant difference between mepolizumab and placebo (MD 6.40, 95% CI 3.15 to 9.65; participants = 576), which indicated a clinically important benefit favouring mepolizumab. A fourth study noted that there was no significant difference but did not provide any data. The two studies in people with eosinophilic asthma showed a reduction in clinically significant exacerbation rates (Risk Ratio 0.52, 95% CI 0.43 to 0.64; participants = 690). However, an analysis of four studies that were not confined to people with eosinophilic asthma indicated considerable heterogeneity and no significant difference in people with one or more exacerbations between mepolizumab and placebo using a random-effects model (Risk Ratio 0.67, 95% CI 0.34 to 1.31; participants = 468; $I^2 = 59\%$). The analysis of serious adverse events indicated a significant difference favouring mepolizumab (Risk ratio 0.49, 95% CI 0.30 to 0.80; participants = 1441; studies = 5; $I^2 = 0\%$). It was not possible to combine the results for adverse events, and we deemed the quality of this evidence to be low.

A single study compared subcutaneous mepolizumab to placebo in 385 adults with severe eosinophilic asthma and found an improvement in HRQoL scores and a reduction in asthma exacerbations, including exacerbations requiring admission to hospital.

Authors' conclusions

It is not possible to draw firm conclusions from this review with respect to the role of mepolizumab in patients with asthma. Our confidence in the results of this review are limited by the fact that the intravenous route is not currently licensed for mepolizumab, and the evidence for the currently licenced subcutaneous route is limited to a single study in participants with severe eosinophilic asthma.

The currently available studies provide evidence that mepolizumab can lead to an improvement in health-related quality of life scores and reduce asthma exacerbations in people with severe eosinophilic asthma.

Further research is needed to clarify which subgroups of patients with asthma could potentially benefit from this treatment. Dosage, ideal dosing regimens and duration of treatment need to be clarified, as the studies included in this review differed in their protocols. There are no studies reporting results from children, so we cannot comment on treatment for this age group. At the present time, larger studies using licenced treatment regimens are required to establish the role of mepolizumab in the treatment of severe asthma.

PLAIN LANGUAGE SUMMARY

Mepolizumab as opposed to placebo for asthma

Review question

We considered in this review whether taking mepolizumab is better than a placebo for people with asthma.

Background

Asthma is an inflammatory lung condition characterised by the narrowing of the airways, breathlessness, a tight chest and reduced quality of life. By the year 2025, there may be up to 400 million people with asthma worldwide. Mepolizumab is one treatment that may help to reduce the symptoms.

Study characteristics

Eight studies compared mepolizumab treatment to a placebo in 1707 patients with asthma. Six studies only included adults. We summarised the results as they relate to quality of life, occurrence of asthma attacks needing hospital admission and side effects of mepolizumab.

Key results

We found that patients with severe asthma who had high levels of eosinophils (inflammatory cells in the blood stream) benefited from taking mepolizumab through improved quality of life and reduced asthma attacks. There was no benefit in terms of lung function. We have avoided making recommendations because we think that further research is needed to clarify aspects such as dosage and length of treatment as well as which patients might benefit the most.

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

IV mepolizumab compared to placebo for asthma						
Patient or population: adults with asthma of varying degrees of severity						
Settings: community						
Intervention: intravenous (IV) mepolizumab						
Comparison: placebo						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	IV mepolizumab				
Change in HRQoL assessed with AQLQ. Scale from 1 to 7 (higher is better) Follow-up: 52 weeks	The mean change in HRQoL ranged from 0.18 to 0.71 units	The mean change in HRQoL in the intervention group was 0.21 units more (0.01 fewer to 0.44 more)	-	682 (2 RCTs)	⊕⊕○○ low ^{a,b}	Trial participants had severe eosinophilic asthma
Change in HRQoL assessed with SGRQ. Scale from: 0 to 100 (lower is better) Follow-up: 32 weeks	The mean change in HRQoL was - 9.0 units	The mean change in HRQoL in the intervention group was 6.4 units lower (3.15 lower to 9.65 lower)	-	382 (1 RCT)	⊕⊕⊕○ moderate ^a	Trial participants had severe eosinophilic asthma
Rate of clinically significant exacerbations - 75 mg mepolizumab versus placebo Follow-up: range 32 to 52 weeks	The mean rate of clinically significant exacerbations on placebo was 1 per patient per year ^c	The mean rate of clinically significant exacerbations in the intervention group was 0.48 less per patient per year (0.57 less to 0.46 less)	Rate ratio 0.52 (0.43 to 0.64)	690 (2 studies)	⊕⊕⊕○ moderate ^a	Trial participants had severe eosinophilic asthma

Rate of clinically significant exacerbations - 250 mg mepolizumab versus placebo Follow-up: 52 weeks	The mean rate of clinically significant exacerbations on placebo was 0.43 per patient per year	The mean rate of clinically significant exacerbations in the intervention group was 0.17 less per patient per year (0.08 less to 0.23 less)	Rate ratio 0.61 (0.46 to 0.81)	307 (1 study)	⊕⊕⊕○ moderate ^a	Trial participants had severe eosinophilic asthma
Rate of clinically significant exacerbations - 750 mg mepolizumab versus placebo Follow-up: 52 weeks	The mean rate of clinically significant exacerbations on placebo was 0.43 per patient per year	The mean rate of clinically significant exacerbations in the intervention group was 0.22 less per patient per year (0.17 less to 0.25 less)	Rate ratio 0.48 (0.36 to 0.64)	311 (1 study)	⊕⊕⊕○ moderate ^a	Trial participants had severe eosinophilic asthma
People with one or more exacerbations Follow-up: 20 to 50 weeks	264 per 1000	177 per 1000 (90 to 345)	Risk ratio 0.67 (0.34 to 1.31)	467 (4 studies)	⊕⊕○○ low ^{a,d}	Variety of asthma severity in the trials
Serious adverse events Follow-up: 20 to 52 weeks	82 per 1000	40 per 1000 (24 to 65)	Risk ratio 0.49 (0.30 to 0.80)	1441 (5 studies)	⊕⊕⊕○ moderate ^a	Variety of asthma severity in the trials

*The basis for the **assumed risk** is the mean control group risk across studies. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

AQLQ: Asthma Quality of Life Questionnaire; **CI:** Confidence interval; **HRQoL:** health-related quality of life; **IV:** intravenous; **RCT:** randomised controlled trial; **SGRQ:** St George's Respiratory Questionnaire.

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

^aThe intravenous route is not currently licenced for mepolizumab; one point deducted for indirectness.

^bThe mean difference is less than the clinical minimally important difference (0.5 units), and no responder analysis is available; one point deducted.

^cPlacebo exacerbation rate per patient per year is the rounded mean of rate in the placebo arm of the two studies (0.43 and 1.75).

^dWide confidence interval increases the uncertainty of this outcome; one point deducted.

BACKGROUND

Description of the condition

A recent global estimate of the number of people currently suffering from asthma is in the region of 300 million, and it is expected that by 2025 the number will increase to 400 million (WHO 2007). The subsequent burden of disease is likely to continue to impose additional pressures on patients, their families and health-care systems (Masoli 2004). The increased incidence in morbidity has been associated with suboptimal delivery of care, including under-treatment with corticosteroids and a limited awareness of the condition amongst patients (Gibson 1993; Kandane-Rathayake 2009).

In the USA, the number of people with asthma increased from 20 million in 2001 to 25 million in 2009 (CDC 2011). Prevalence rates are slightly higher among children (10%) than among adults (8%) (CDC 2011; CDC 2012), with considerable variation among different ethnic groups. Between 2008 and 2010, asthma prevalence rates in the USA were 14.1% among multiracial individuals, 11.2% among blacks, 9.4% among Alaska Natives, 9.4% among other Native Americans, 7.7% among whites and 5.2% among those of Asian descent (CDC 2011). Globally, the prevalence of wheezing symptoms in children varies geographically, with the UK having the highest recorded prevalence of current wheezing at 32.3% and Ethiopia the lowest at 1.7% (Patel 2008).

For many people, asthma has an important impact on quality of life (Clayton 2005) and on financial considerations (Wu 2007). In the USA, approximately 10 million people experience asthma exacerbations each year (Krishnan 2006), and in the UK, over 65,000 hospital admissions for asthma were recorded in 2005 and 2006 (NHS 2011).

In recent years, clinical guidelines have been produced for the management of asthma at national (e.g. BTS/SIGN 2014; NIH 2007) and international (GINA 2012) levels. Several risk factors for asthma have been identified, including triggers such as allergens, chemical irritants and tobacco smoke, but asthma-related mortality and morbidity remain a major health concern (Braman 2006). On the other hand, the condition can also be controlled and health-related quality of life (HRQoL) maintained for considerable periods (WHO 2011).

Description of the intervention

One of the core pathological features of asthma is considered to be eosinophilic infiltration of the bronchial mucosa, which triggers an inflammatory response. Mepolizumab is a humanised monoclonal antibody against interleukin-5 (IL-5) that has been shown to inhibit eosinophilic airway inflammation. A number of studies have been conducted in young adults (> 12 years old) and adults with

recurrent severe asthma exacerbations and signs of eosinophilic inflammation (Haldar 2009; Nair 2009; Pavord 2012). The results of these studies suggest that inhibiting eosinophilic inflammation by monoclonal antibodies may be associated with a reduced risk of acute exacerbations of asthma and a reduction in eosinophil count.

How the intervention might work

Proteins secreted by eosinophils cause damage to the epithelium, initiating vasodilatation, smooth muscle contraction and increased mucous secretion, which in turn is associated with increased airway hyperresponsiveness, asthma symptoms and airway narrowing (Liu 2013).

Mepolizumab is a key monoclonal antibody inhibiting IL-5, which is the main cytokine involved in eosinophil activation and recruitment. This intervention might work by preventing the initiation of the inflammatory response. Mepolizumab is administered intravenously as either a one-off dose of 2.5 to 10 mg/kg or monthly doses of 75 mg, 250 mg or 750 mg given for a period ranging from 16 to 52 weeks. Mepolizumab can also be given subcutaneously.

Why it is important to do this review

In a recently published meta-analysis of seven randomised placebo-controlled trials on 1131 adults, mepolizumab was shown to reduce the risk of exacerbations and improve quality of life in people with eosinophilic asthma, but did not lead to a significant improvement in lung function (Liu 2013).

It is important to do this review so that the evidence presented and the judgements made in Liu 2013 are available and placed in context within *The Cochrane Library*. Our review will also set the stage for future updates as more evidence becomes available.

OBJECTIVES

To compare the effects of mepolizumab with placebo on exacerbations and HRQoL in adults and children with chronic asthma.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs). We included studies reported as full text, those published as abstracts only and

unpublished data. Included trials were a minimum of 16 weeks in duration.

Types of participants

We included both adults and children with a diagnosis of asthma. We focused on collating data from people who have been reported as having eosinophilic asthma to analyse these individuals as a subgroup. We examined individual articles in order to determine how this group should be defined.

Individuals with congenital heart disease and respiratory comorbidities such as cystic fibrosis were excluded, as were current smokers.

Types of interventions

We included trials comparing mepolizumab with placebo. We planned to include the following cointerventions provided they were not part of the randomised treatment: leukotriene antagonists, inhaled bronchodilators (including long-acting beta₂-agonists), systemic and inhaled steroids, oral aminophylline and macrolide antibiotics.

Studies that initiated a reduction in standard asthma management as part of the protocol were excluded. [Nair 2009](#) included a reduction in the dose of prednisolone in the second phase of the trial. Therefore, only phase one of this trial was included as patients remained on their standard asthma treatment during this four-week period.

Types of outcome measures

Primary outcomes

1. HRQoL (as measured by a validated questionnaire)
2. Asthma exacerbation as defined by a hospital admission or treatment with a course of oral corticosteroids
3. Serious adverse events

Secondary outcomes

1. Measures of lung function: forced expiratory flow in one second (FEV₁), peak expiratory flow rate (PEFR)
2. Asthma symptoms
3. Adverse events/side effects
4. Eosinophil counts in peripheral blood, sputum or bronchioalveolar lavage fluid

Reporting one or more of the outcomes listed here in the trial was not an inclusion criterion for the review.

Search methods for identification of studies

Electronic searches

We identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Trials Search Co-ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO. We also handsearched respiratory journals and meeting abstracts (please see [Appendix 1](#) for further details). We searched all records in the CAGR using the search strategy in [Appendix 2](#).

We also conducted a search of ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) trials portal (www.who.int/ictrp/en/).

We searched all databases from their inception to the present and imposed no restriction on language of publication. The search was first conducted in November 2013 and was updated in November 2014.

Searching other resources

We checked the bibliographies of all primary studies and review articles for additional references. We searched relevant manufacturers' websites for trial information.

We searched for errata and retractions relevant to the included studies published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed) and planned to report the date this was done within the review if this was an issue.

Data collection and analysis

Selection of studies

Two review authors (NW, CP) independently screened titles and abstracts of all the potential studies identified in the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full-text study reports/publications, and two review authors (NW, CP) independently screened the full text and identified studies for inclusion, identifying and recording reasons for excluding the ineligible studies. We planned to resolve any disagreement through discussion or, if required, by consulting a third author (SJM); however, this was not necessary. We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and a '[Characteristics of excluded studies](#)' table.

Data extraction and management

We used a data collection form to record study characteristics and outcome data that had been piloted on at least one study in the review. Two review authors (LB, NW) extracted the following study characteristics from included studies.

1. Methods: study design, total duration of study, details of any run-in period, number of study centres and location, study setting, withdrawals and date of study.
2. Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparator, concomitant medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of trial authors.

Two review authors (LB, NW) independently extracted outcome data from included studies. We noted in the 'Characteristics of included studies' table if outcome data were not reported in a usable way. We planned to resolve disagreements by consensus or by involving a third author (CP), but this was not necessary. One review author (KD) transferred data into Review Manager (RevMan). We double-checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (SJM) spot-checked study characteristics for accuracy against the trial report.

Assessment of risk of bias in included studies

Two review authors (LB, NW) independently assessed risk of bias for each study using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We planned to resolve any disagreements by discussion or by involving another author (SJM), but this was not necessary. We assessed the risk of bias according to the domains:

1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.

We graded each potential source of bias as high, low or unclear, and provided a quotation from the study report together with a justification for this judgement in the 'Risk of bias' table. We summarised the risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for an unblinded outcome assessment, risk of bias for all-cause mortality may be very different than that for a patient-reported pain scale). Where information on risk of bias related to unpublished data or corre-

spondence with a trialist, we noted this in the 'Risk of bias' table. When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome.

We conducted the review according to this published protocol and have reported any deviations from it in the 'Differences between protocol and review' section of the systematic review.

Measures of treatment effect

We analysed dichotomous data as risk ratios and rate ratios and continuous data as mean differences or standardised mean differences, which are presented with 95% confidence intervals. We entered data presented on a scale with a consistent direction of effect. However, on one occasion we had to use the risk ratio as one study had reported this (Haldar 2009).

We have undertaken meta-analyses only where this was meaningful (i.e. if the treatments, participants and underlying clinical question were sufficiently similar for pooling to make sense).

Where multiple trial arms were reported in a single trial (Flood-Page 2007; Pavord 2012), we combined the relevant arms (750 mg, 250 mg, 75 mg in Pavord 2012 and 750 mg, 250 mg in Flood-Page 2007) when appropriate.

In future updates of this review, we will narratively describe skewed data reported as medians and interquartile ranges. Where multiple trial arms are reported in a single trial, we will include only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) are combined in the same meta-analysis, we will halve the control group to avoid double-counting.

Unit of analysis issues

No cross-over studies or cluster randomised trials were identified for inclusion in this version of the review. If cross-over trials are identified in the future, data from a paired analysis will be sought from the trial report or authors in order to appropriately include data in the review using the inverse variance method. If cluster randomised trials are identified in the future, then analyses will be at the level of the individual while allowing for the clustering in the data by using the intracluster correlation coefficient. If this is not reported in the trial, then it will be imputed from similar studies.

Dealing with missing data

Although unnecessary for this version of the review, we may contact investigators or study sponsors for future versions in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study is identified as an abstract only). Where this is not possible, and the missing data are thought to introduce serious bias, we will explore the impact of including such studies in the overall assessment of results by a sensitivity analysis.

Assessment of heterogeneity

Statistical heterogeneity between studies was assessed visually by inspection of the forest plots and using the Chi^2 test (a P value < 0.10 was considered significant due to the low power of the test). The I^2 statistic was also calculated; this describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). Values of I^2 range from 0% to 100%, with 0% representing no heterogeneity and 100% representing considerable heterogeneity.

For this review, heterogeneity as reported using the I^2 statistic was defined as follows.

- 0% to 40%: heterogeneity might not be important.
- 30% to 60%: may represent moderate heterogeneity.
- 50% to 90%: may represent substantial heterogeneity.
- 75% to 100%: considerable heterogeneity.

Assessment of reporting biases

If we are able to pool more than 10 trials for future versions, we will create and examine a funnel plot to explore possible small study biases and publication bias.

Data synthesis

In view of the considerable clinical heterogeneity between the included studies, we used a random-effects model.

Data on outcomes were combined at 6 months and 12 months. Where data for other time points were reported, these were also described.

Subgroup analysis and investigation of heterogeneity

Provided sufficient studies were included, we planned to carry out subgroup analyses according to:

1. age (0 to 5 years, 6 to 16 years, 17 years and older);
 2. eosinophilic individuals versus non-eosinophilic individuals; and
 3. dose of intervention (posthoc subgroup identified);
- using the outcomes:
1. HRQoL; and
 2. asthma symptoms.

If more studies are included in the future, we will use the formal test for subgroup interactions in [RevMan](#).

Sensitivity analysis

We planned to carry out the following sensitivity analyses if sufficient studies were included.

1. Excluding studies with an overall high risk of bias.
2. Excluding cross-over trials and cluster randomised trials.

Summary of findings table

We created 'Summary of findings' tables using the following outcomes.

1. HRQoL.
2. Asthma exacerbation as defined by a hospital admission or treatment with a course of oral corticosteroids.
3. Serious adverse events.

We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence as it relates to the studies that contribute data to the meta-analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) using GRADEpro software. We have justified all decisions to downgrade or upgrade the quality of studies using footnotes, and we have made comments to aid the reader's understanding of the review where necessary.


RESULTS

Description of studies

Results of the search

We identified 154 records in our literature searches: 129 in database searches in November 2013 and a further 25 in November 2014 (Figure 1). Eight studies met our inclusion criteria ('Characteristics of included studies' table), and two others were included in the ongoing studies category ('Characteristics of ongoing studies' table). The eight included studies had 25 records: one for [Buttner 2003](#); seven for [Flood-Page 2003](#), one for [Flood-Page 2007](#), four for [Halder 2009](#), one for [Leckie 2000](#); five for [Nair 2009](#); two for [Ortega 2014](#) and four for [Pavord 2012](#). The remaining 127 records were excluded for various reasons ('Characteristics of excluded studies' table).

Figure 1. Study flow diagram



Included studies

We included eight studies ('Characteristics of included studies' table), involving 1707 total participants distributed as follows: Buttner 2003, 19; Flood-Page 2003, 24; Flood-Page 2007, 362; Haldar 2009, 61; Leckie 2000, 24; Nair 2009, 20; Ortega 2014, 576 Pavord 2012, 621. Table 1 compares the design, numbers, interventions and patient groups in the included trials. The severity of asthma among participants varied from mild atopic asthma to persistent eosinophilic asthma with recurrent exacerbations. The mepolizumab was administered exclusively through intravenous route in seven of the studies, with dosage varying from 2.5 mg/kg or 10 mg/kg, or 75 mg, 250 mg and 750 mg with different dosing regimens over a range of treatment periods. Only one study had a subcutaneous (SC) arm, with a dose of 100 mg (Ortega 2014).

Excluded studies

We excluded 127 records from the review. Of these, 119 (94%) were excluded because mepolizumab had not been included in the study, 4 (3%) were excluded because they did not include a placebo arm, another 2 (2%) were excluded because the focus was on steroid reduction, 1 (1%) was non-randomised, and the remaining study (1%) was conducted on healthy participants without a diagnosis of asthma ('Characteristics of excluded studies' table).

Risk of bias in included studies

Details of our risk of bias assessments are available in the 'Characteristics of included studies' table, and a summary of our assessment can be seen in Figure 2 and Figure 3.

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.




Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Buttner 2003	?	?	+	+	?	+
Flood-Page 2003	?	?	+	+	+	+
Flood-Page 2007	?	?	+	+	+	-
Haldar 2009	+	?	+	+	+	+
Leckie 2000	?	?	+	+	+	+
Nair 2009	+	+	+	+	+	+
Ortega 2014	+	+	+	+	+	+
Pavord 2012	+	+	+	+	+	+

Allocation

We deemed only three studies (Nair 2009; Pavord 2012; Ortega 2014) to be at low risk of bias for both random sequence generation and allocation concealment. We judged Haldar 2009 to be at low risk of bias for random sequence generation, but its bias with regard to allocation concealment was unclear. The risk of bias for the remaining four studies (Buttner 2003; Flood-Page 2003; Flood-Page 2007; Leckie 2000) was unclear for both random sequence generation and allocation concealment (Figure 3).

Blinding

With regard to performance bias and detection bias, we determined that all eight studies were at low risk of bias (Figure 3).

Incomplete outcome data

In terms of attrition bias, we considered seven of the studies to be at low risk of bias, while the risk of bias in Buttner 2003 was unclear (Figure 3).

Selective reporting

One study noted that there was no significant difference in HRQoL but did not provide any data (Flood-Page 2007), so we considered it to be at high risk of bias. We deemed all other studies to be at low risk of bias as there was no apparent evidence of selective reporting.

Effects of interventions

See: [Summary of findings for the main comparison](#) Intravenous mepolizumab compared to placebo for asthma; [Summary of findings 2](#) Subcutaneous mepolizumab compared to placebo for asthma

Primary outcomes

HRQoL (as measured by a validated questionnaire)

Three studies (participants = 1044) measured quality of life using the Asthma Quality of Life Questionnaire (AQLQ) (Flood-Page 2007; Haldar 2009; Pavord 2012). One study noted that there was no significant difference but did not provide any data (Flood-Page 2007).

Intravenous mepolizumab versus placebo

Pavord 2012 reported data at 52 weeks for three different dose groups of Intravenous (IV) mepolizumab (75 mg, 250 mg, 750 mg), which we combined and presented as one group. Haldar 2009 reported data at 50 weeks. Combining the two studies, Analysis 1.1 showed a non-significant difference between IV mepolizumab and placebo (MD 0.21, 95% CI - 0.01 to 0.44; participants = 682), favouring IV mepolizumab. Our confidence in this result is low, as the mean difference is less the clinical minimally important difference of 0.5 units, and no responder analysis is reported ([Summary of findings for the main comparison](#)).

Ortega 2014 measured quality of life using the St. George's Respiratory Questionnaire (SGRQ) and found a significant difference favouring IV mepolizumab over the placebo (MD 6.40, 95% CI 3.15 to 9.65; participants = 382; Analysis 1.2). We only have moderate confidence in this result, as IV delivery is not currently a licenced route of administration for mepolizumab ([Summary of findings for the main comparison](#)).

Subcutaneous mepolizumab versus placebo

Ortega 2014 measured quality of life using the St. George's Respiratory Questionnaire (SGRQ) and found a significant difference between subcutaneous (SC) mepolizumab and placebo, in favour of mepolizumab (MD - 7.00, 95% CI - 10.19 to - 3.81; participants = 385; Analysis 2.1). We have moderate confidence in this result from a single study ([Summary of findings 2](#)).

Asthma exacerbation as defined by a hospital admission or treatment with a course of oral corticosteroids

Six studies (participants = 1664) reported on asthma exacerbations (Flood-Page 2003; Flood-Page 2007; Haldar 2009; Nair 2009; Pavord 2012; Ortega 2014). Increase in oral corticosteroids is included in the definition of exacerbation for three studies (Haldar 2009; Ortega 2014; Pavord 2012). Two studies did not include an increase in oral corticosteroids in the definition of exacerbation (Flood-Page 2007; Nair 2009), while one study did not provide a definition of exacerbation (Flood-Page 2003).

IV Mepolizumab versus placebo

Four studies (Flood-Page 2003; Flood-Page 2007; Haldar 2009; Nair 2009) reported the number of patients experiencing an exacerbation. Analysis 1.6, which used a random-effects model, did not show a significant difference between IV mepolizumab and placebo (Risk Ratio 0.67, 95% CI 0.34 to 1.31; participants = 468

$I^2 = 59\%$). Our confidence in this result is low due to the wide confidence intervals ([Summary of findings for the main comparison](#)). [Pavord 2012](#) reported the rate ratio of exacerbations for each of the three different dose groups of IV mepolizumab compared to placebo. [Ortega 2014](#) reported the percentage reduction in the rate ratio for clinically significant exacerbations for 75 mg IV mepolizumab compared to placebo. We combined the results for groups taking the 75 mg dose from these studies, both of which included participants with severe eosinophilic asthma.

[Analysis 1.3](#) shows similar results for the rate of clinically significant exacerbations, which include a course of oral steroids, emergency department (ED) visit or admission. For the 75 mg dose, the rate of ED visits or hospital admissions for people on mepolizumab was half that of the placebo group (rate ratio 0.52, 95% CI 0.43 to 0.64; participants = 690; studies = 2). For the 250 mg dose, the result was similar (rate ratio 0.61, 95% CI 0.46 to 0.81; participants = 307; studies = 1) and also for the 750 mg dose (rate ratio 0.48, 95% CI 0.36 to 0.64; participants = 311; studies = 1). Our confidence in this result is moderate, as IV delivery is not currently a licenced delivery route for mepolizumab ([Summary of findings for the main comparison](#)).

[Analysis 1.4](#) shows the rate ratio for the combined results of these two studies in terms of exacerbations requiring hospital admission, and there is not a significant difference for the 75 mg mepolizumab dose (rate ratio 0.61, 95% CI 0.33 to 1.13; participants = 690; studies = 2). The 750 mg IV mepolizumab group compared to placebo showed a reduction in the risk of being admitted to hospital (rate ratio 0.37, 95% CI 0.16 to 0.86; participants = 311; studies = 1). The 250 mg dose did not show a statistically significant reduction (rate ratio 0.65, 95% CI 0.31 to 1.37; participants = 307; studies = 1), but the difference between doses was not significant (test for subgroup differences: $\text{Chi}^2 = 1.14$, degree of freedom (df) = 2 ($P = 0.57$), $I^2 = 0\%$).

[Analysis 1.5](#) shows the combined results on exacerbations requiring a visit to the ED or hospital admission. For the 75 mg dose, there was a significant reduction in the exacerbation rate for this outcome (rate ratio 0.52, 95% CI 0.31 to 0.87; participants = 690; studies = 2), and although the reduction in rate was similar for the other doses, it did not reach statistical significance (250 mg dose: rate ratio 0.58, 95% CI 0.30 to 1.12; participants = 307; studies = 1; and 750 mg dose: rate ratio 0.52, 95% CI 0.27 to 1.02; participants = 311; studies = 1). Again there was no significant difference between the results according to dose (test for subgroup differences: $\text{Chi}^2 = 0.08$, df = 2 ($P = 0.96$), $I^2 = 0\%$).

SC Mepolizumab versus placebo

[Ortega 2014](#) also found a reduction in the rate of all of the above types of exacerbations favouring SC mepolizumab in comparison to placebo. [Analysis 2.2](#) shows the results for hospital admission (rate ratio 0.31, 95% CI 0.11 to 0.91; participants = 385; studies = 1). [Analysis 2.3](#) shows the reduction in either ED visits or hospital

admission (rate ratio 0.39, 95% CI 0.18 to 0.83; participants = 385; studies = 1). [Analysis 2.4](#) shows the reduction in clinically significant exacerbations (rate ratio 0.47, 95% CI 0.35 to 0.63; participants = 385; studies = 1). We have moderate confidence in these results from a single study ([Summary of findings 2](#)).

Serious adverse events

Five studies (participants = 1640) reported information on serious adverse events.

[Nair 2009](#) stated that there were no serious adverse events, while [Pavord 2012](#) reported that the overall frequency of serious adverse events was similar across treatment groups and that no serious life-threatening anaphylactic reactions were observed; however, three patients in the IV mepolizumab groups died during the study for reasons that the physician investigator judged to be unrelated to the treatment.

[Flood-Page 2007](#) reported nine serious adverse events: four in patients receiving placebo (vertigo, bladder carcinoma, unintended pregnancy and asthma exacerbation), three in patients receiving IV mepolizumab 250 mg (hydrocephalus/cerebrovascular disorder, constipation and gastrointestinal disturbance), and two in patients receiving IV mepolizumab 750 mg (asthma exacerbation). None of these serious adverse events was considered to be related to the study medication, and there were no significant differences between the treatment groups.

[Halder 2009](#) reported that hospitalisation for asthma was a serious adverse effect for 10% (3/29) of participants in the IV mepolizumab arm and 34% (11/32) in the placebo arm.

[Ortega 2014](#) reported that the incidence of serious adverse events (including asthma-related events) was 7% in the intravenous mepolizumab group, 8% in the subcutaneous mepolizumab group, and 14% in the placebo group.

[Analysis 1.7](#) indicated that there was a significant difference between IV mepolizumab versus placebo (Risk Ratio 0.49, 95% CI 0.30 to 0.80; participants = 1441; studies = 5; $I^2 = 0\%$), favouring IV mepolizumab. Our confidence in this result is moderate, as IV delivery is not currently a licenced route of administration for mepolizumab ([Summary of findings for the main comparison](#)).

Secondary outcomes

Measures of lung function: forced expiratory flow in one second (FEV₁), peak expiratory flow rate (PEFR)

Seven studies (participants = 1688) report on lung function ([Flood-Page 2003](#); [Flood-Page 2007](#); [Halder 2009](#); [Leckie 2000](#); [Nair 2009](#); [Pavord 2012](#); [Ortega 2014](#)).

IV Mepolizumab versus placebo

[Flood-Page 2003](#) reported no difference between IV mepolizumab and placebo for median FEV₁ and median PEF_R at 12 weeks ([Table 2](#)).

[Flood-Page 2007](#) reported mean change from placebo for FEV₁ (L) and PEF_R L/min at weeks 12 and 20. [Analysis 1.8](#) indicates there was no significant difference in FEV₁ between IV mepolizumab and placebo at week 20. [Analysis 1.9](#) shows a significant difference for IV mepolizumab 250 mg compared to placebo (MD 13.49; 95% CI 0.71 to 26.27), but not for the 750 mg compared to placebo group (MD 3.42, 95% CI - 9.40 to 16.24). However, the test for subgroup difference was not significant (Chi² = 1.19, df = 1 (P = 0.280), I² = 15.9%).

[Halder 2009](#) and [Nair 2009](#) reported no significant difference in post-bronchodilator FEV₁ (L) between IV mepolizumab and placebo at one year and six weeks, respectively ([Analysis 1.10](#)). [Nair 2009](#) also reported no difference between IV mepolizumab and placebo for percentage predicted FEV₁ after bronchodilation ([Analysis 1.11](#)).

[Pavord 2012](#) found no significant difference between any dose of IV mepolizumab and placebo in pre-bronchodilator FEV₁ (mL) at one year ([Analysis 1.13](#)).

[Leckie 2000](#) reports no significant difference between IV mepolizumab and placebo in late asthmatic reaction (maximum percentage fall in FEV₁) ([Analysis 1.14](#)).

[Ortega 2014](#) reported a statistically significant difference favouring IV mepolizumab for both pre- and post-bronchodilator FEV₁ (MD 0.10 L; 95% CI 0.01 to 0.19); (MD 0.15 L, 95% CI 0.05 to 0.24), ([Analysis 1.10](#); [Analysis 1.12](#)).

SC Mepolizumab versus placebo

[Ortega 2014](#) reported a statistically significant difference favouring SC mepolizumab for both pre- and post-bronchodilator FEV₁ (MD 0.10, 95% CI 0.02 to 0.18; participants = 385; studies = 1 and MD 0.14, 95% CI 0.04 to 0.23; respectively) ([Analysis 2.5](#); [Analysis 2.6](#)).

Asthma symptoms

Five studies (participants = 1640) measured asthma symptoms ([Flood-Page 2007](#); [Halder 2009](#); [Nair 2009](#); [Pavord 2012](#); [Ortega 2014](#)).

IV Mepolizumab versus placebo

[Flood-Page 2007](#) reported results at 20 weeks using the asthma summary symptom score. [Nair 2009](#) reported data at 4 weeks using a symptom score, a cough score and the Juniper Asthma Cough Questionnaire (JACQ) score. [Halder 2009](#) reported data at one year using the visual analogue scale symptom score and a

modified Juniper Asthma Control Score. [Pavord 2012](#) reported data using the asthma control questionnaire at one year. [Ortega 2014](#) reported data at 32 weeks using the five-item Asthma Control Questionnaire (ACQ-5).

There were no significant differences between IV mepolizumab at 250 mg or 750 mg and placebo using an asthma symptom score or the JACQ, but there was a significant difference between 75 mg and placebo (MD - 0.30, 95% CI - 0.55 to - 0.04; participants = 690; studies = 2; [Analysis 1.15](#)), although test for subgroup difference was again non-significant (Chi² = 0.81, df = 2 (P = 0.67), I² = 0%).

SC Mepolizumab versus placebo

There was also a statistically significant improvement in symptoms on SC mepolizumab compared to placebo (MD - 0.44, 95% CI - 0.64 to - 0.24; participants = 385; studies = 1); [Analysis 2.7](#)). However, there was no responder analysis, and this mean difference is less than the minimal clinically important difference of - 0.5 units.

Adverse events/side effects

Six studies (participants = 1664) reported adverse events ([Flood-Page 2003](#); [Flood-Page 2007](#); [Halder 2009](#); [Nair 2009](#); [Pavord 2012](#); [Ortega 2014](#)).

[Flood-Page 2003](#) reported that all of the 24 volunteers completed the study without reporting adverse events.

[Flood-Page 2007](#) reported that there were no significant differences between the treatment groups for any adverse events reported. The most common adverse events (at least 5% of participants in any treatment group) were upper respiratory tract infection, asthma, headache, rhinitis, bronchitis, sinusitis, viral infection, injury, back pain, nausea and pharyngitis.

[Halder 2009](#) reported that one patient withdrew due to rash after mepolizumab infusion.

[Nair 2009](#) reported that one patient in the IV mepolizumab group withdrew because of increased shortness of breath, thought to be due to heart failure. One patient in the placebo group died six months after the study because of sudden cardiac arrest; one patient in the IV mepolizumab group reported aches and tiredness when prednisolone was reduced, and one patient in the placebo group had hypoadrenalism when prednisolone was reduced.

[Pavord 2012](#) found that the most frequently reported adverse events were headache (27 (17%) individuals given placebo, 32 (21%) given 75 mg IV mepolizumab, 32 (21%) given 250 mg IV mepolizumab, and 32 (21%) given 750 mg IV mepolizumab) and nasopharyngitis (24 (15%), 34 (22%), 33 (22%), and 29 (19%) for the four groups, respectively). The most frequently reported drug-related adverse event was infusion-related reaction (e.g. non-allergic reactions), which was reported by 10 (6%) patients given placebo, 8 (5%) given 75 mg mepolizumab, 12 (8%) given 250 mg

IV mepolizumab, and 19 (12%) given 750 mg IV mepolizumab. Hypersensitivity deemed to be possibly related to investigational product was reported by three patients (2%) given placebo, none given 75 mg IV mepolizumab, one (< 1%) given 250 mg IV mepolizumab, and two (1%) given 750 mg IV mepolizumab.

In the [Ortega 2014](#) study, the overall incidence of adverse events during treatment was similar in the three groups (84% in the IV mepolizumab group, 78% in the SC mepolizumab group, and 83% in the placebo group). The most frequently reported adverse events were nasopharyngitis and headache. The incidence of adverse events that were considered by the study investigators to be related to a study drug was 17% in the IV mepolizumab group, 20% in the SC mepolizumab group, and 16% in the placebo group. The incidence of injection-site reactions was more frequent in the SC mepolizumab group (9%) than in the IV mepolizumab group or the placebo group (3% in each).

Eosinophil counts in peripheral blood, sputum or bronchioalveolar lavage fluid

All eight studies (participants = 1707) report on eosinophil counts ([Buttner 2003](#); [Flood-Page 2003](#); [Flood-Page 2007](#); [Haldar 2009](#); [Leckie 2000](#); [Nair 2009](#); [Pavord 2012](#); [Ortega 2014](#)).

[Buttner 2003](#) found that “[a]sthmatic patients received three consecutive intravenous infusions of either IV mepolizumab (250 mg or 750 mg per dose) or placebo at 4-week intervals. Remarkably, almost a complete disappearance of peripheral blood eosinophils was observed after the first infusion. Eosinophil counts remained low or absent until week 24, 12 weeks after the last infusion. In contrast, there were no significant changes in eosinophil counts in the placebo group. The marked fall in peripheral blood eosinophils was accompanied by a significant decrease in ECP concentrations. The kinetics of ECP (serum eosinophil cationic protein) levels resembled the eosinophil counts. These qualitative and quantitative changes were observed in both treatment groups without a significant difference between the 250 and 750 mg dosage.”

[Flood-Page 2003](#) found that at four weeks after the first dose of IV mepolizumab, there was a significant decrease in peripheral blood eosinophil counts in the actively treated group when compared with placebo ($P = 0.002$). This decrease was maintained throughout the dosing period and was still evident at the time of the repeat bronchoscopy and bone marrow aspirate, [at] Week 10 ($P = 0.02$). There was a median reduction of 100% from baseline of eosinophils in the actively treated group at Weeks 4 and 10 (interquartile range, 67-100%). A return of blood eosinophil counts toward baseline was observed at a mean of 9 weeks after the

last dose (range 4-20 weeks, data not shown). IV mepolizumab produces a 79% median reduction in bronchoalveolar lavage fluid (BALF) eosinophils (interquartile range, 42-99%) ($P = 0.4$ when compared with placebo) ([Table 3](#)).

[Flood-Page 2007](#) found a significant reduction in the eosinophil counts in the 250 mg and 750 mg groups at week 1 ($P < 0.001$). Also, 32 patients gave samples at baseline and week 12; 17 had sputum eosinophils > 3%. There was a significant decrease in both the 250 mg ($P = 0.006$) and the 750 mg group ($P = 0.004$), which was also significant when compared to placebo.

[Haldar 2009](#) reports a significant difference between IV mepolizumab and placebo for geometric mean sputum eosinophil percentage during exacerbation, and a sputum eosinophil count > 3% during exacerbation (% of episodes), [Table 4](#). The study also reports, “[T]he geometric mean of eosinophil counts in the blood during the treatment phase, as compared with the baseline value, was reduced by a factor of 6.6 in the mepolizumab group and by a factor of 1.1 in the placebo group, with the changes from baseline differing between the groups by a factor of 6.1 (95% CI, 4.1 to 8.9; $P < 0.001$).”

Results from [Leckie 2000](#) are presented in [Table 5](#). There was a significant reduction in blood eosinophils pre-allergen challenge in the group given mepolizumab 10 mg/kg. Postinhaled allergen, there was a significant reduction in blood eosinophils in both groups given mepolizumab. There was a dose dependent reduction in sputum eosinophils in both mepolizumab groups. This result reached statistical significance in the 10 mg/kg group.

[Ortega 2014](#) found a significant decrease in both treatment groups in blood eosinophil count.

Results from [Nair 2009](#) can be found in [Table 6](#). In phase 1 of the trial, a single infusion of mepolizumab 750 mg resulted in a reduction in the number of sputum and blood eosinophils.

[Pavord 2012](#) found that compared with placebo, the ratios of geometric means at 52 weeks showed that the drug reduced blood eosinophil counts (ratios of geometric means 0.22, 95% CI 0.18 to 0.27) in individuals given 75 mg mepolizumab ($P < 0.0001$; ratios of geometric means 0.14; 95% CI 0.12 to 0.18), in those given 250 mg mepolizumab, ($P < 0.0001$; ratios of geometric means 0.12; 95% CI 0.09 to 0.14) and in those given 750 mg mepolizumab, ($P < 0.0001$). In the subgroup of 94 participants who had sputum induction, the drug also caused decreases in sputum eosinophil counts compared with placebo (ratio 0.68, 95% CI 0.13 to 3.52), in individuals given 75 mg mepolizumab ($P = 0.6429$; ratios of geometric means 0.35, 95% CI 0.08 to 1.52), in those given 250 mg mepolizumab ($P = 0.1577$; 0.12 95% CI 0.02 to 0.56) and in those given 750 mg ($P = 0.0082$).

ADDITIONAL SUMMARY OF FINDINGS *[Explanation]*

Subcutaneous mepolizumab compared to placebo for asthma						
Patient or population: adults with severe eosinophilic asthma Settings: community Intervention: subcutaneous (SC) mepolizumab Comparison: placebo						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	SC mepolizumab				
Change in HRQoL assessed with SGRQ. Scale from: 0 to 100 (lower is better) Follow-up: 32 weeks	The mean HRQoL was 9.0 units	The mean HRQoL - SGRQ in the intervention group was 7 units fewer (10.19 fewer to 3.81 fewer)	-	385 (1 RCT)	⊕⊕⊕○ moderate ^a	
Rate of exacerbations requiring admission Follow-up: 32 weeks	The mean rate of exacerbations requiring admission on placebo was 0.10 per patient per year	The mean rate of exacerbations requiring ED visit or admission in the intervention group was 0.07 less per patient per year (0.01 less to 0.09 less)	Rate ratio 0.31 (0.11 to 0.91)	385 (1 RCT)	⊕⊕⊕○ moderate ^a	
Rate of exacerbations requiring ED or admission Follow-up: 32 weeks	The mean rate of exacerbations requiring ED or admission on placebo was 0.20 per patient per year	The mean rate of exacerbations requiring ED or admission in the intervention group was 0.12 less per patient per year (0.03 less to 0.16 less)	Rate ratio 0.39 (0.18 to 0.83)	385 (1 RCT)	⊕⊕⊕○ moderate ^a	

Rate of clinically significant exacerbations Follow-up: 32 weeks	The mean rate of clinically significant exacerbations on placebo was 1.75 per patient per year	The mean rate of clinically significant exacerbations in the intervention group was 0.93 less per patient per year (0.65 less to 1.14 less)	Rate ratio 0.47 (0.35 to 0.63)	385 (1 RCT)	⊕⊕⊕○ moderate ^a
Asthma symptoms measured on Asthma Control Questionnaire Scale from: 0 to 6 (lower is better) ^b Follow-up: 32 weeks	The mean change in asthma symptoms was –0.5 units	The mean asthma symptoms in the intervention group was 0.44 units fewer (0.64 fewer to 0.24 fewer)	-	385 (1 RCT)	⊕⊕⊕○ low ^{a,c}

*The basis for the **assumed risk** was the event rate in the placebo arm of the single included study. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **ED:** emergency department; **HRQoL:** health-related quality of life; **RCT:** randomised controlled trial; **SC:** subcutaneous; **SGRQ:** St George's Respiratory Questionnaire.

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

^aThis finding is from a single study so we do not know how well this will match further research; one point deducted.

^bThe minimal clinically important difference on this scale is 0.5 units.

^cThe mean difference is less than the clinical minimally important difference (0.5 units), and no responder analysis is available; one point deducted.

DISCUSSION

Summary of main results

Eight studies met our inclusion criteria for this systematic review (Buttner 2003; Flood-Page 2003; Flood-Page 2007; Haldar 2009; Leckie 2000; Nair 2009; Pavord 2012; Ortega 2014). Six studies included adults participants only, while Pavord 2012 and Ortega 2014 included participants aged 12 years and over, with a mean age of around 50 years and no separate reporting of results in adolescents. In total, 1707 people participated.

The results suggest that mepolizumab leads to an improvement in HRQoL and a reduction in asthma exacerbation rates for people with severe eosinophilic asthma randomised to received mepolizumab compared to placebo, with no significant increase in serious adverse events on treatment.

With regard to the secondary outcome measures, mepolizumab did not lead to a significant increase in measures of lung function (FEV₁ or PEFr). There was no significant difference in asthma symptoms using an asthma symptom score or the JACQ between IV mepolizumab at 250 mg or 750 mg and placebo. However, there was a significant difference between 75 mg IV mepolizumab and placebo (although a non-significant test for subgroup difference) and between SC mepolizumab and placebo, in participants with severe eosinophilic asthma. There were minimal significant adverse events related to mepolizumab, but headache and nasopharyngitis were commonly reported side effects. Due to the variety of dosing regimens and protocols, direct comparison of eosinophil counts in peripheral blood, sputum and bronchoalveolar fluid was not possible.

Peripheral blood eosinophil counts, sputum eosinophil counts and eosinophil counts in bronchoalveolar fluid all showed a significant reduction after treatment with mepolizumab.

There were only two studies that included paediatric patients, down to the age of 12 years old (Ortega 2014; Pavord 2012), but there was no separate reporting of results in adolescents, so we have insufficient evidence to undertake a subgroup analysis based on age.

Overall completeness and applicability of evidence

Although the precise definition of asthma exacerbation is subject to debate, with the consequent variability in reporting, it is nevertheless considered to be one of the core outcomes to be measured in asthma studies (Fuhlbrigge 2012). We found evidence of a reduction in the rate of clinically significant exacerbations in adults with severe eosinophilic asthma given IV or SC mepolizumab. Health-related quality of life (HRQoL) improved with intervention compared to placebo by a mean of seven units in the single study using SGRQ (Ortega 2014), but the mean change in AQLQ was less

than the minimal clinically important difference and was not accompanied by responder analyses. These two primary outcomes are clinically important outcomes for the individual. Secondary outcomes of asthma symptoms scores, cough scores, lung function and airway hyperreactivity were not influenced by mepolizumab. Most studies examined eosinophils, inflammatory markers and mediators using a combination of peripheral blood, sputum and bronchoalveolar lavage and showed reductions in those who received mepolizumab. The clinical relevance of this finding to patients may not be clinically important. There were no studies in children under 12 and only two studies included children aged 12 years or older (but without disaggregating results for the participating adolescents). The asthma population examined in this review was too heterogeneous to draw any conclusions about the general asthma population.

Quality of the evidence

Using the GRADE system, we considered the quality of evidence for IV mepolizumab to be limited, as this is not a licenced delivery route (so we would regard this as indirect evidence). We felt that the HRQoL results were of moderate quality, and further research may have an important effect on the results presented. There was a risk of reporting bias in the assessment of HRQoL for one paper: Flood-Page 2007 noted no significant changes in HRQoL but did not provide any data, thus no data could be included in the meta-analysis. We are aware of the limitations in some of the studies and have detailed them in the results section, Figure 2 and Figure 3. We determined that the risk of performance bias and detection bias based on the blinding processes was low in all eight studies. We also found that selection bias was low in only three studies for both random sequence generation and allocation concealment (Nair 2009; Ortega 2014; Pavord 2012) but unclear in four others (Buttner 2003; Flood-Page 2003; Flood-Page 2007; Leckie 2000). Haldar 2009 had a low risk of bias for random sequence generation, but the risk of bias was unclear with respect to allocation concealment. Publication bias was not formally assessed through the construction of a funnel plot due to the small number of included studies. However, we performed a thorough search strategy, including searching conference abstracts and ongoing studies, in order to identify unpublished studies.

Potential biases in the review process

We acknowledge the potential for publication bias in this review, as it is possible that we failed to identify unpublished trials that may have provided positive or negative outcomes, which in turn could have altered the treatment benefits. However, to the best of our knowledge, we identified a significant number of trials meeting our inclusion criteria through comprehensive and systematic database searches. We tried to address any study selection bias by

having two review authors who independently evaluated all the identified studies. We also ensured that the assessment of each trial was consistently in line with the inclusion criteria.

Agreements and disagreements with other studies or reviews

Our review follows on from [Liu 2013](#), which also considered the efficacy of mepolizumab in patients with asthma. The present review includes one extra study ([Ortega 2014](#)), and its findings are consistent with [Liu 2013](#). Both reviews highlight the need for further research in this area.

AUTHORS' CONCLUSIONS

Implications for practice

It is not possible to draw firm conclusions from this review with respect to the role of mepolizumab versus placebo in patients with asthma, due partly to the heterogeneity of the studies.

The currently available studies provide evidence that mepolizumab leads to an improvement in health-related quality of life scores and a reduction of asthma exacerbations in people with severe eosinophilic asthma ([Haldar 2009](#); [Nair 2009](#); [Pavord 2012](#); [Ortega 2014](#)). There was also an improvement in asthma symptom scores in subjects with persistent eosinophilic asthma when using subcutaneous mepolizumab and 75 mg mepolizumab intravenously ([Ortega 2014](#)). Mepolizumab did not lead to a significant increase in measures of lung function.

Further research is needed to clarify which subgroups of patients with asthma could potentially benefit from this treatment. Dosage, ideal dosing regimens and duration of treatment need to be clarified, as the studies included in this review differed in their protocols. There were only two studies that included children (over

the age of 12), and these do not provide sufficient evidence on which to base a recommendation for use. At the present time, larger studies are required to establish the role of mepolizumab in the treatment of asthma.

Implications for research

There needs to be further research on mepolizumab in children, with a focus on the core outcomes of exacerbations and HRQoL but also asthma symptoms and lung function (in children who can perform respiratory function tests).

In adults, the evidence available so far suggests that there is an improvement in HRQoL and frequency of acute exacerbations in participants with severe eosinophilic asthma. However, there needs to be further research to ascertain the optimum dose and regimen for mepolizumab therapy, as the studies included in this review used a wide range of dosing regimens.

ACKNOWLEDGEMENTS

We would particularly like to acknowledge the excellent support and assistance from Emma Welsh, Liz Stovold and Emma Jackson of the Cochrane Airways Review Group, together with the greatly appreciated guidance from Chris Cates (Cochrane Airways Review Group Co-ordinating Editor). The support provided by librarians Judith Scammel, Jane Appleton and Hilary Garrett at St George's University of London is also greatly appreciated.

We are very grateful to Chris Cates, the Contact Editor who commented critically on the review.

The information provided by Prof Peter Barnes regarding an included study ([Leckie 2000](#)) is also much appreciated.

The background and methods section of this review is based on a standard template used by Cochrane Airways Group.

REFERENCES

References to studies included in this review

Buttner 2003 *[published data only]*

Buttner C, Lun A, Spletstoesser T, Kunkel G, Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. *European Respiratory Journal* 2003;**21**(5):799–803.

Flood-Page 2003 *[published data only]*

Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway

[comment]. *American Journal of Respiratory and Critical Care Medicine* 2003;**167**(2):199–204. [4900100000013790]

Flood-Page PT, Menzies-Gow AN, Phipps S, Compton C, Walls C, Barnes NC, et al. Reduction of tissue eosinophils in mild atopic asthmatics by an anti-IL-5 monoclonal antibody (Mepolizumab) is associated with inhibition of tenascin deposition with the bronchial epithelial basement [Abstract]. *American Journal of Respiratory and Critical Care Medicine* 2002;**165**(Suppl 8):B42.

Flood-Page PT, Menzies-Gow AN, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial

basement membrane of mild atopic asthmatics. *Journal of Clinical Investigation* 2003;**112**(7):1029–36.

Kay AB, Flood-Page PT, Menzies-Gow AN, Robinson DS. Effect of anti-IL-5 (mezolizumab) on airway eosinophils in asthmatics. *Allergy and Clinical Immunology International* 2004;**Suppl 1**:298–301. [4900100000051661]

Menzies-Gow AN, Flood-Page PT, Compton C, Walls C, Sehmi R, Robinson DS, et al. A double-blind placebo-controlled, parallel group study to assess the effect of mepolizumab (humanised monoclonal anti-il-5-antibody) on bone marrow and peripheral blood eosinophils and eosinophil progenitors in atopic asthmatics [Abstract]. *American Journal of Respiratory and Critical Care Medicine*. 2002; Vol. 165, issue Suppl 8:B50.

Menzies-Gow AN, Flood-Page PT, Sehmi R, Burman J, Hamid Q, Robinson DS, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. *The Journal of Allergy and Clinical Immunology* 2003;**111**(4):714–9. [4900100000015225]

Phipps S, Flood-Page PT, Menzies-Gow AN, Wangoo A, Barnes N, Barkans J, et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin procollagen III and lumican in the reticular basement membrane of human atopic asthmatics [Abstract]. *The Journal of Allergy and Clinical Immunology*. 2003; Vol. 111, issue 2 Suppl:S278.

Flood-Page 2007 {published data only}

Flood-Page PT, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. *American Journal of Respiratory and Critical Care Medicine* 2007;**176**(11):1062–71.

Haldar 2009 {published data only}

Gupta S, Halder P, Hargadon B, Sousa A, Marshall RP, Wardlaw AJ, et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma [Abstract]. *American Thoracic Society International Conference*; 2009 May 15-20 San Diego. 2009:A3641.

Haldar P, Brightling C, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab (Anti-IL5) and exacerbation frequency in refractory eosinophilic asthma [Abstract]. *Proceedings of the American Thoracic Society International Conference*; 2009 May 15-20; San Diego. *American Journal of Critical Care and Respiratory Medicine*. 2009; Vol. 179:A3638.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. *New England Journal of Medicine* 2009;**360**(10):973–84.

Haldar P, Brightling CE, Singapuri A, Hargadon B, Gupta S, Monteiro W, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. *The Journal of Allergy and Clinical Immunology* 2014;**133**(3):921–3. [CRS:

490012600009453; EMBASE: 2014156329; PUBMED: 24418480]

Leckie 2000 {published data only}

Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *The Lancet* 2000;**356**(9248):2144–8.

Nair 2009 {published data only}

Ayars AG, Altman LC, Potter-Perigo S, Radford K, Wight TN, Nair P. Sputum hyaluronan and versican in severe eosinophilic asthma. *International Archives of Allergy and Immunology* 2013;**161**(1):65–73.

Ayars AG, Altman LC, Potter-Perigo S, Wight TN, Nair P. Sputum hyaluronan as a biomarker of airway remodeling in severe asthma [Abstract]. *Journal of Allergy and Clinical Immunology*. 2011; Vol. 127, issue 2 Suppl 1:AB8.

NCT00292877. The effects of a humanized anti-IL-5 monoclonal antibody (SB-240563) on asthma control, airway eosinophilia and the degree to which corticosteroid treatment can be reduced to maintain control. <https://clinicaltrials.gov/ct2/show/NCT00292877> (accessed 16 January 2015).

Nair P, Pizzichini M, Kjarsgaard M, Inman M, Efthimiadis A, Pizzichini E, et al. Prednisone sparing effect of mepolizumab on eosinophilic bronchitis with or without asthma a randomized placebo controlled trial [Abstract]. *American Thoracic Society International Conference*; 2008 May 16-21; Toronto. 2008:A568[#509].

Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. *New England Journal of Medicine* 2009;**360**(10):985–93.

Ortega 2014 {published data only}

NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. <https://clinicaltrials.gov/ct2/show/NCT01691521> (accessed 16 January 2015).

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *New England Journal of Medicine* 2014;**371**(13):1198–207. [CRS: 4900126000019751; EMBASE: 25199059; PUBMED: 25199059]

Pavord 2012 {published data only}

NCT01000506. A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma. <https://clinicaltrials.gov/ct2/show/NCT01000506> (accessed 16 January 2015).

Ortega H, Li H, Suruki R, Albers F, Gordon D, Yancey S. Cluster analysis and characterization of response to mepolizumab: A step closer to personalized medicine for patients with severe asthma. *Annals of the American Thoracic*

Society 2014;**11**(7):1011–7. [CRS: 4900126000015693; PUBMED: 24983709]
 Pavord I, Korn S, Howarth P, Bleecker E, Buhl R, Keene O, et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma [Abstract]. Proceedings of the European Respiratory Society 22nd Annual Congress; 2012 Sep 1-5; Vienna. *European Respiratory Journal*. 2012; Vol. 40, issue Suppl 56:366 [349].
 Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *The Lancet* 2012;**380**(9842):651–9.

References to studies excluded from this review

Alvarez-Cuesta 1994 {published data only}

Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. *Journal of Allergy and Clinical Immunology* 1994;**93**(3):556–66.

Armentia 1992 {published data only}

Armentia A, Arranz M, Martin JM, de la Fuente R, Sanchez P, Barber D, et al. Evaluation of immune complexes after immunotherapy with wheat flour in bakers' asthma. *Annals of Allergy* 1992;**69**(5):441–4.

Ayres 2004 {published data only}

Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. *Allergy* 2004;**59**(7):701–8.

Bel 2014 {published data only}

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *New England Journal of Medicine* 2014;**371**(13):1189–97. [CENTRAL: 1013105; CRS: 4900126000019750; EMBASE: 25199060; PUBMED: 25199060] NCT01691508. MEA115575: A randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab adjunctive therapy to reduce steroid use in subjects with severe refractory asthma. <https://clinicaltrials.gov/ct2/show/NCT01691508> (accessed 15 July 2015).

Berger 2003 {published data only}

Berger W, Gupta N, McAlary M, Fowler-Taylor A, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. *Annals of Allergy, Asthma & Immunology* 2003;**91**(2):182–8. [4900102000000524]

Blanken 2012 {published data only}

Blanken M, Rovers M, Sanders E, Bont L. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent

wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. *Contemporary Clinical Trials* 2012;**33**(6):1287–92.

Blanken 2013 {published data only}

Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *New England Journal of Medicine* 2013;**368**(19):1791–9. [4900100000077900]

Boulet 1997 {published data only}

Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. *American Journal of Respiratory and Critical Care Medicine* 1997;**155**(6):1835–40.

Bousquet 2004 {published data only}

Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. *Chest* 2004;**125**(4):1378–86.

Bousquet 2011 {published data only}

Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. *Allergy* 2011;**66**(5):671–8.

Brown 2007 {published data only}

Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. *Allergy* 2007;**62**(2):149–53. [4900100000019948]

Bryant 1975 {published data only}

Bryant DH, Burns MW, Lazarus L. Identification of IgG antibody as a carrier of reaginic activity in asthmatic patients. *The Journal of Allergy and Clinical Immunology* 1975;**56**(6):417–28.

Bryant 1975a {published data only}

Bryant DH, Burns MW, Lazarus L. The correlation between skin tests, bronchial provocation tests and the serum level of IgE specific for common allergens in patients with asthma. *Clinical Allergy* 1975;**5**(2):145–57.

Buhl 2000a {published data only}

Buhl R, Kunkel G, Soler M, Bensch G, Wolfe J, Noga O, et al. RhuMAB-25 improves asthma-specific quality of life in patients with allergic asthma. *European Respiratory Journal* 2000;**16**(Suppl 31):465s.

Buhl 2000b {published data only}

Buhl R, Soler M, Fox H, Ashby M, McAlary M, Cooper J, et al. Recombinant humanized monoclonal antibody (rhuMAB) E25 in the prevention of serious asthma exacerbations. *European Respiratory Journal* 2000;**16**(Suppl 31):277s.

Buhl 2002 {published data only}

Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. *European Respiratory Journal* 2002;**20**(1):73–8.

- Bush 1985** *{published data only}*
 Bush RK, Taylor SL, Nordlee JA, Busse WW. Soybean oil is not allergenic to soybean-sensitive individuals. *The Journal of Allergy and Clinical Immunology* 1985;**76**(2 Pt 1):242–5.
- Busse 2001** *{published data only}*
 Busse WW, Corren J, Lanier BQ, Mcalary M, Fowler-Taylor A, Della Cioppa G, et al. Omalizumab, Anti-IgE Recombinant Humanized Monoclonal Antibody, for the Treatment of Severe Allergic Asthma. *The Journal of Allergy and Clinical Immunology* 2001;**108**(2):184–90. [490010000010636]
- Busse 2008** *{published data only}*
 Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. *American Journal of Respiratory and Critical Care Medicine* 2008;**178**(10):1002–8.
- Caffarelli 2000** *{published data only}*
 Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. *Allergy* 2000;**55**(12):1142–7.
- Castro 2010** *{published data only}*
 Castro M, Mathur S, Hargreave F, Xie F, Young J, Wilkins HJ, et al. Reslizumab in the treatment of poorly controlled asthma in patients with eosinophilic airway inflammation [Abstract]. *Annals of Allergy, Asthma & Immunology* 2010; **105**(5 Suppl):A43.
- Castro 2011** *{published data only}*
 Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. *American Journal of Respiratory and Critical Care Medicine* 2011;**184**(10):1125–32.
- Chandra 1989** *{published data only}*
 Chandra RK, Singh G, Shridhara B. Effect of feeding whey hydrolysate, soy and conventional cow milk formulas on incidence of atopic disease in high risk infants. *Annals of Allergy* 1989;**63**(2):102–6.
- Chervinsky 2003** *{published data only}*
 Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. *Annals of Allergy, Asthma & Immunology* 2003;**91**(2):160–7. [490010000015346]
- Clavel 1998** *{published data only}*
 Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. *Allergy* 1998;**53**(5):493–8.
- Corren 2003** *{published data only}*
 Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. *The Journal of Allergy and Clinical Immunology* 2003;**111**(1):87–90.
- Corren 2010** *{published data only}*
 Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4/alpha antagonist, in patients with asthma. *American Journal of Respiratory and Critical Care Medicine* 2010;**181**(8):788–96.
- Cullell-Young 2002** *{published data only}*
 Cullell-Young M, Bayes M, Leeson PA. Omalizumab: Treatment of allergic rhinitis, treatment of asthma. *Drugs of the Future* 2002;**27**(6):537–45.
- De Boever 2014** *{published data only}*
 De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen JJ, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial. *The Journal of Allergy and Clinical Immunology* 2014;**133**(4):989–996. [CENTRAL: 984687; CRS: 4900126000011203; EMBASE: 2014224342; PUBMED: 24582316]
- Djukanovic 2004** *{published data only}*
 Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. *American Journal of Respiratory and Critical Care Medicine* 2004;**170**(6):583–93.
- Ebner 1989** *{published data only}*
 Ebner H, Neuchrist C, Havelec L, Kraft D. [Comparative studies of the effectiveness of specific immunotherapy in house dust mite allergy] [Vergleichende Untersuchungen zur Wirksamkeit einer spezifischen Immuntherapie bei Hausstaubmilben-Allergie]. *Wiener Klinische Wochenschrift* 1989;**101**(15):504–11.
- Eckman 2010** *{published data only}*
 Eckman JA, Sterba PM, Kelly D, Alexander V, Liu MC, Bochner BS, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. *The Journal of Allergy and Clinical Immunology* 2010;**125**(4):889–895.e7.
- El-Nawawy 2000** *{published data only}*
 El-Nawawy AA, Massoud MN, El-Nazzar SY, Ramy BB. Pulmonary tuberculosis as a cause of recurrent wheezy chest: the value of serological diagnosis using IgG antibodies to mycobacterium 38 kDa antigen. *Journal of Tropical Pediatrics* 2000;**46**(1):53–4.
- Fahy 1997** *{published data only}*
 Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. *American Journal of Respiratory and Critical Care Medicine* 1997;**155**(6):1828–34.
- Fahy 1999** *{published data only}*
 Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, et al. Effect of aerosolized anti-IgE (E25) on airways responses to inhaled allergen in asthmatic subjects. *American Journal of Respiratory and Critical Care Medicine* 1999;**160**(3):1023–7. [490010000006519]

- Finn 2003** {published data only}
Finn A, Gross G, Van Bavel J, Lee T, Windom H, Everhard F, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. *The Journal of Allergy and Clinical Immunology* 2003;**111**(2):278–84.
- Frew 1998** {published data only}
Frew AJ. Effects of anti-IgE in asthmatic subjects. *Thorax* 1998;**53**(Suppl 2):S52–7. [490010000010183]
- Garcia 2013** {published data only}
Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. *Chest* 2013;**144**(2): 411–9. [CENTRAL: 872766; CRS: 4900100000089187; EMBASE: 2013508319; PUBMED: 23579324]
- Gauvreau 2011** {published data only}
Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. *American Journal of Respiratory and Critical Care Medicine* 2011;**183**(8):1007–14.
- Gauvreau 2014a** {published data only}
Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. *New England Journal of Medicine* 2014;**370**(22):2102–10. [CENTRAL: 991614; CRS: 4900126000014666; 4900126000014666; PUBMED: 24846652]
- Gauvreau 2014b** {published data only}
Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Mayers I, Carlsten C, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. *Clinical and Experimental Allergy* 2014;**44**(1): 29–37. [CENTRAL: 961627; CRS: 4900126000003111; EMBASE: 2013812052; PUBMED: 24224471]
- Gauvreau 2014c** {published data only}
Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. *Science Translational Medicine* 2014;**6**(243):243ra85. [CENTRAL: 994063; CRS: 4900126000015683; PUBMED: 24990880]
- Gevaert 2013** {published data only}
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. *The Journal of Allergy and Clinical Immunology* 2013;**131**(1): 110–6.e1.
- Gordon 1972** {published data only}
Gordon VH, Caplinger KJ, Meade JHJ, Thompson C. Correlation of type specific fluorescent antibodies to ragweed with symptomatology: double-blind study. *Annals of Allergy* 1972;**30**(9):507–17.
- Greenberg 1991** {published data only}
Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ. Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections. *Progress in Clinical and Biological Research* 1991;**367**:179–86.
- Han 2009** {published data only}
Han JQ, Zhu YX. Efficacy and regulation of humoral immunity of jade screen powder as an adjunct therapy in children with asthma [搜索关键词]. *Zhongguo Dang Dai Er Ke Za Zhi [Chinese Journal of Contemporary Pediatrics]* 2009;**11**(7):587–8.
- Hanania 2011** {published data only}
Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial [Summary for patients]. *Annals of Internal Medicine* 2011;**154**(9):573–82.
- Hanania 2013** {published data only}
Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. *American Journal of Respiratory and Critical Care Medicine* 2013;**187**(8):804–11. [4900100000077549]
- Hanania 2014** {published data only}
Hanania NA, Noonan MJ, Corren J, Korenblat P, Zheng Y, Putnam W, et al. Efficacy and safety of lebrikizumab in severe uncontrolled asthma: Results from the lute and verse phase II randomized, double-blind, placebo-controlled trials. *The Journal of Allergy and Clinical Immunology* 2014;**133**(2 Suppl):AB402. [CENTRAL: 985853; CRS: 4900126000010490; EMBASE: 71351759]
- Hill 1982** {published data only}
Hill DJ, Smart IJ, Hosking CS. Specific cellular and humoral immunity in children with grass pollen asthma. *Clinical Allergy* 1982;**12**(1):83–9.
- Hodsman 2013** {published data only}
Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, et al. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. *British Journal of Clinical Pharmacology* 2013;**75**(1):118–28.
- Holgate 2004** {published data only}
Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clinical and Experimental Allergy* 2004;**34**(4):632–8.
- Hoshino 2012** {published data only}
Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. *Respiration; International Review of Thoracic Diseases* 2012;**83**(6):520–8.
- Humbert 2005** {published data only}
Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy

- (GINA 2002 step 4 treatment): INNOVATE. *Allergy* 2005; **60**(3):309–16.
- Humbert 2008** *{published data only}*
Humbert M, Berger W, Rapatz G, Turk F. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. *Allergy* 2008; **63**(5):592–6. [4900100000021856]
- Humbert 2009** *{published data only}*
Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. *Allergy* 2009; **64**(1):81–4.
- Jacquemin 1995** *{published data only}*
Jacquemin MG, Saint-Remy JM. Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes. *Therapeutic Immunology* 1995; **2**(1):41–52.
- Jutel 2005** *{published data only}*
Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. *The Journal of Allergy and Clinical Immunology* 2005; **116**(3):608–13.
- Kang 1988** *{published data only}*
Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach asthma. *Journal of Asthma* 1988; **25**(4):205–18.
- Kips 2003** *{published data only}*
Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. *American Journal of Respiratory and Critical Care Medicine* 2003; **167**(12):1655–9.
- Kon 2001** *{published data only}*
Kon OM, Sihra BS, Loh LC, Barkans J, Compton CH, Barnes NC, et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. *European Respiratory Journal* 2001; **18**(1):45–52. [4900100000011111]
- Kopp 2009** *{published data only}*
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and comorbid seasonal allergic asthma. *Clinical and Experimental Allergy* 2009; **39**(2):271–9.
- Kopp 2013** *{published data only}*
Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. *Pediatric Allergy and Immunology* 2013; **24**(5):427–33. [CENTRAL: 870929; CRS: 4900100000087210; EMBASE: 2013483684; PUBMED: 23799935]
- Kulus 2010** *{published data only}*
Kulus M, Hebert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. *Current Medical Research and Opinion* 2010; **26**(6): 1285–93.
- Lanier 2003** *{published data only}*
Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. *Annals of Allergy, Asthma & Immunology* 2003; **91**(2):154–9. [CENTRAL: 440250; CRS: 4900100000015345; PUBMED: 12952109]
- Lanier 2009** *{published data only}*
Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. *The Journal of Allergy and Clinical Immunology* 2009; **124**(6):1210–6. [CENTRAL: 731495; CRS: 4900100000024431; EMBASE: 2009623072; PUBMED: 19910033]
- Laviolette 2013** *{published data only}*
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. *The Journal of Allergy and Clinical Immunology* 2013; **132**(5):1086–96.e5. [CENTRAL: 874819; CRS: 4900126000001561; EMBASE: 2013693094; PUBMED: 23866823]
- Leynadier 2004** *{published data only}*
Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, et al. Effect of omalizumab in health care workers with occupational latex allergy. *The Journal of Allergy and Clinical Immunology* 2004; **113**(2):360–1.
- Lizaso 2008** *{published data only}*
Lizaso MT, Tabar AI, Garcia BE, Gomez B, Algorta J, Asturias JA, et al. Double-blind, placebo-controlled *Alternaria alternata* immunotherapy: in vivo and in vitro parameters. *Pediatric Allergy and Immunology* 2008; **19**(1): 76–81.
- Massanari 2009** *{published data only}*
Massanari M, Kianifard F, Zeldin R K, Geba G P. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma. *Allergy and Asthma Proceedings* 2009; **30**(5):534–9. [CENTRAL: 728392; CRS: 4900100000024363; PUBMED: 19467177]
- Massanari 2010** *{published data only}*
Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. *The Journal of Allergy and Clinical Immunology* 2010; **125**(2):383–9.
- Mathur 2011** *{published data only}*
Mathur S, Castro M, Hargreave F, Xie F, Wilkins HJ, Henkel T, et al. Efficacy of reslizumab in patients with poorly controlled eosinophilic asthma: subgroup analysis of patients with nasal polyps [Abstract]. *Journal of Allergy and Clinical Immunology*. 2011; Vol. 127, issue 2 Suppl 1: AB84.

- Metzger 1998** *{published data only}*
Metzger WJ, Fick RB, Bush RK, Busse W, Casale T, Chodosh S. Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (rhu MAbE25) [Abstract]. *The Journal of Allergy and Clinical Immunology* 1998;**101**(1 Suppl):S231.
- Milgrom 1999** *{published data only}*
Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. RhuMAb-E25 Study Group. *New England Journal of Medicine* 1999;**341**(26):1966–73.
- Milgrom 2001** *{published data only}*
Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). *Pediatrics* 2001;**108**(2):E36.
- Modlin 1977** *{published data only}*
Modlin JF, Smith DH, Harding L. Clinical trials of bivalent A/New Jersey/76-A/Victoria/75 influenza vaccines in high-risk children. *Journal of Infectious Diseases* 1977;**136**(Suppl):S626–31.
- Moss 1987** *{published data only}*
Moss RB, Hsu YP, Kwasnicki JM, Sullivan MM, Reid MJ. Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: correlation of rye group I antigen-specific IgG1 with clinical response. *The Journal of Allergy and Clinical Immunology* 1987;**79**(2):387–98.
- Nair 2010** *{published data only}*
Nair P, Kjarsgaard M, Armstrong S, Efthimiadis A, O'Byrne PM, Hargreave FE. Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. *The Journal of Allergy and Clinical Immunology* 2010;**126**(2):404–6. [CENTRAL: 759797; CRS: 490010000025377; PUBMED: 20621343]
- NCT00802438** *{published data only}*
NCT00802438. Eosinophilic airway inflammation: relationship to remodeling and modulation by mepolizumab. <https://clinicaltrials.gov/ct2/show/NCT00802438> (accessed 15 July 2015).
- NCT01366521** *{published data only}*
NCT01366521. A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevated blood eosinophil levels. <https://clinicaltrials.gov/ct2/show/NCT01366521> (accessed 15 July 2015).
- NCT01471327** *{published data only}*
NCT01471327. A single blind, placebo controlled, parallel group, single ascending intravenous dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SB-240563 (mepolizumab) in healthy Japanese male subjects. <https://clinicaltrials.gov/ct2/show/NCT01471327> (accessed 15 July 2015).
- NCT01691859** *{published data only}*
NCT01691859. MEA115666: A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial. <https://clinicaltrials.gov/ct2/show/NCT01691859> (accessed 15 July 2015).
- NCT01842607** *{published data only}*
NCT01842607. MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials. <https://clinicaltrials.gov/ct2/show/NCT01842607> (accessed 15 July 2015).
- NCT02135692** *{published data only}*
NCT02135692. Study 201312: a multi-centre, open-label, study of mepolizumab in a subset of subjects with a history of life threatening/seriously debilitating asthma who participated in the MEA115661 trial. <http://clinicaltrials.gov/show/NCT02135692> (accessed 15 July 2015). [CRS: 4900126000021136]
- NCT02293265** *{published data only}*
NCT02293265. Identification and description of severe asthma patients in a cross-sectional study—the IDEAL study. <http://clinicaltrials.gov/show/NCT02293265> (accessed 15 July 2015). [CRS: 4900126000021134]
- Niven 2008** *{published data only}*
Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. *Respiratory Medicine* 2008;**102**(10):1371–8.
- Noga 2003** *{published data only}*
Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. *International Archives of Allergy and Immunology* 2003;**131**(1):46–52. [4900100000015254]
- Noga 2008** *{published data only}*
Noga O, Hanf G, Kunkel G, Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. *International Archives of Allergy and Immunology* 2008;**146**(1):66–70. [CENTRAL: 628876; CRS: 4900100000021809; PUBMED: 18087163]
- Noonan 2013** *{published data only}*
Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. *The Journal of Allergy and Clinical Immunology* 2013;**132**(3):567–74.e12. [CENTRAL: 872124; CRS: 4900100000088876; EMBASE: 2013545353; PUBMED: 23726041]
- Oba 2004** *{published data only}*
Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. *The Journal of Allergy and Clinical Immunology* 2004;**114**(2):265–9.
- Oh 2013** *{published data only}*
Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA. A randomized, controlled trial to evaluate the

- effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. *Respiratory Research* 2013;**14**(1):93. [CENTRAL: 871533; CRS: 490010000090024; EMBASE: 2013599844; 490010000090024; PUBMED: 24050312]
- Ohashi 1997** *{published data only}*
Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, et al. Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis. *Annals of Allergy, Asthma & Immunology* 1997;**79**(3):213–20.
- Ohman 1984** *{published data only}*
Ohman JLJ, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. *The Journal of Allergy and Clinical Immunology* 1984;**74**(3 Pt 1):230–9.
- Ohta 2009** *{published data only}*
Ohta K, Miyamoto T, Amagasaki T, Yamamoto M, 1304 Study Group. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. *Respirology* 2009;**14**(8):1156–65.
- Ong 2005** *{published data only}*
Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. *The Journal of Allergy and Clinical Immunology* 2005;**116**(3):558–64.
- Parker 2010** *{published data only}*
Parker J, Brazinsky S, Miller DS, Nayak A, Korenblat PE, Sari S, et al. Randomized, double-blind, placebo-controlled, multicenter phase 2A study to evaluate the effect of a humanized interleukin-9 monoclonal antibody (MEDI-528) on exercise-induced bronchospasm [Abstract]. *American Journal of Respiratory and Critical Care Medicine* 2010;**181**(Meeting Abstracts):A5394.
- Pauli 1984** *{published data only}*
Pauli G, Bessot JC, Bigot H, Delaume G, Hordle DA, Hirth C, et al. Clinical and immunologic evaluation of tyrosine-adsorbed *Dermatophagoides pteronyssinus* extract: a double-blind placebo-controlled trial. *The Journal of Allergy and Clinical Immunology* 1984;**74**(4 Pt 1):524–35.
- Piper 2013** *{published data only}*
Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. *European Respiratory Journal* 2013;**41**(2):330–8.
- Prieto 2006** *{published data only}*
Prieto L, Gutierrez V, Colas C, Tabar A, Perez-Frances C, Bruno L, et al. Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma. *International Archives of Allergy and Immunology* 2006;**139**(2):122–31.
- Pui 2010** *{published data only}*
Pui M, Lay JC, Alexis NE, Carlsten C. Flow cytometry to identify leukocyte sub-populations in blood and induced sputum in asthmatic and healthy volunteers exposed to diesel exhaust [Abstract]. *Allergy, Asthma, and Clinical Immunology* 2010;**6**(Suppl 3):P7.
- Rose 2009** *{published data only}*
Rose MA, Gruendler M, Schubert R, Kitz R, Schulze J, Zielen S. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics. *Vaccine* 2009;**27**(38):5259–64.
- Sakamoto 1984** *{published data only}*
Sakamoto Y, Nakagawa T, Ito K, Miyamoto T. Solid-phase radioimmunoassay for the measurement of IgG antibodies specific for the house dust mite, *Dermatophagoides farinae*. *Annals of Allergy* 1984;**52**(4):303–8.
- Scheerens 2011** *{published data only}*
Scheerens H, Arron J R, Su Z, Zheng Y, Putnam W, Erickson RW, et al. Predictive and pharmacodynamic biomarkers of interleukin-13 blockade: effect of lebrikizumab on late phase asthmatic response to allergen challenge [Abstract]. *The Journal of Allergy and Clinical Immunology*. 2011; Vol. 127, issue 2 Suppl 1:AB164.
- Scheerens 2014** *{published data only}*
Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. *Clinical and Experimental Allergy* 2014;**44**(1):38–46. [CENTRAL: 961626; CRS: 490012600003110; EMBASE: 2013812053; PUBMED: 24131304]
- Siergiejko 2011** *{published data only}*
Siergiejko Z, Swiebocka E, Smith N, Peckitt C, Leo J, Peachey G, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. *Current Medical Research and Opinion* 2011;**27**(11):2223–8.
- Silk 1998** *{published data only}*
Silk H, Zora J, Goldstein J, Tinkelman D, Schiffman G. Response to pneumococcal immunization in children with and without recurrent infections. *Journal of Asthma* 1998;**35**(1):101–12.
- Silkoff 2004** *{published data only}*
Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. *Pediatrics* 2004;**113**(4):e308–12.
- Simoes 2007** *{published data only}*
Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. *Journal of Pediatrics* 2007;**151**(1):34–42, 42.e1.
- Singh 2010** *{published data only}*
Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. *BMC Pulmonary Medicine* 2010;**10**:3.

Slavin 2009 *{published data only}*

Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. *The Journal of Allergy and Clinical Immunology* 2009;**123**(1):107–113.e3. [490010000022846]

Soler 2001 *{published data only}*

Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. *European Respiratory Journal* 2001;**18**(2):254–61.

Sorkness 2013 *{published data only}*

Sorkness CA, Wildfire JJ, Calatroni A, Mitchell HE, Busse WW, O'Connor GT, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. *The Journal of Allergy & Clinical Immunology in Practice* 2013;**1**(2):163–71. [CENTRAL: 991371; CRS: 490012600012068; PUBMED: 24565455]

Schoeger 2007 *{published data only}*

Schoeger ZM, Eliraz A, Asher I, Berkman N, Elbirt D. The beneficial effects of Xolair (Omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV - The Israeli arm of the INNOVATE study. *Israel Medical Association Journal* 2007;**9**(6):472–5.

Sugaya 1994 *{published data only}*

Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. *JAMA* 1994;**272**(14):1122–6.

Swanson 2014 *{published data only}*

Swanson BN, Wang L, Ming J, Hamilton JD, Teper A, Dicioccio T, et al. Exhaled nitric oxide (FENO) and t-helper 2 cell biomarkers: can they predict treatment response to dupilumab, an il-4ra antibody, in an eosinophilic asthma population?. *The Journal of Allergy and Clinical Immunology* 2014;**133**(2 Suppl):AB85. [CENTRAL: 985863; CRS: 4900126000010595; EMBASE: 71351035]

Szymaniak 1998 *{published data only}*

Szymaniak L. An attempt to block histamine release from basophils granulocytes with antibodies obtained as a result of long-term immunization [Proba blokowania uwalniania histaminy z granulocytow zasadochlonnych przeciwcialami uzyskanymi w wyniku dlugotrwej immunizacji bakteriami]. *Annales Academiae Medicae Stetinensis* 1998;**44**:45–64.

Tanaka 1993 *{published data only}*

Tanaka Y, Ueda K, Miyazaki C, Nakayama M, Kusuhara K, Okada K, et al. Trivalent cold recombinant influenza live vaccine in institutionalized children with bronchial asthma and patients with psychomotor retardation. *Pediatric Infectious Disease Journal* 1993;**12**(7):600–5.

Terr 1969 *{published data only}*

Terr AI. Immunologic bases for injection therapy of allergic diseases. *Medical Clinics of North America* 1969;**53**(6):1257–64.

Van Rensen 2009 *{published data only}*

Van Rensen EL, Evertse CE, Van Schadewijk WA, Van Wijngaarden S, Ayre G, Mauad T, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. *Allergy* 2009;**64**(1):72–80.

Vignola 2004 *{published data only}*

Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. *Allergy* 2004;**59**(7):709–17.

Wark 2003 *{published data only}*

Wark PA, Hensley MJ, Salto N, Boyle MJ, Toneguzzi RC, Epid GD, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. *The Journal of Allergy and Clinical Immunology* 2003;**111**(5):952–7.

Wenzel 2009 *{published data only}*

Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. *American Journal of Respiratory and Critical Care Medicine* 2009;**179**(7):549–58. [4900100000023441]

Wenzel 2013 *{published data only}*

Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. *New England Journal of Medicine* 2013;**368**(26):2455–66.

Zetterstrom 1972 *{published data only}*

Zetterstrom O, Fagerberg E, Wide L. An investigation of pollen extracts from different deciduous trees in patients with springtime allergy in Sweden. *Acta Allergologica* 1972;**27**(1):15–21.

Zhu 2013 *{published data only}*

Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, et al. Population-based efficacy modelling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy. *The AAPS Journal* 2013;**15**(2):559–70.

Zielen 2013 *{published data only}*

Zielen S, Lieb A, De La Motte S, Wagner F, de Monchy J, Fuhr R, et al. Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma. *International Archives of Allergy and Immunology* 2013;**160**(1):102–10.

References to ongoing studies**NCT01520051 2012** *{published data only}*

NCT01520051. The efficacy of mepolizumab treatment on rhinovirus induced asthma exacerbations. <https://>

clinicaltrials.gov/show/NCT01520051 (accessed 15 July 2015).

NCT02281318 2014 *[published data only]*

NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. <http://clinicaltrials.gov/show/NCT02281318> (accessed 15 July 2015). [CRS: 4900126000021132]

Additional references

Braman 2006

Braman SS. The global burden of asthma. *Chest* 2006;**130** (1 Suppl):4S–12S.

BTS/SIGN 2014

British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. *Thorax* 2014;**69**(Suppl. 1):i1–i192.

CDC 2011

Centers for Disease Control and Prevention. Trends in asthma prevalence, health care, and mortality in the United States, 2001–2010. www.cdc.gov/nchs/data/databriefs/db94.htm (accessed 10 December 2012).

CDC 2012

Centers for Disease Control and Prevention. Vital signs. www.cdc.gov/vitalsigns/asthma/ (accessed 10 December 2013).

Clayton 2005

Clayton S. Paediatric asthma: overcoming barriers to an improved quality of life. *British Journal of Nursing* 2005; Vol. 14, issue 2:80–5.

Fuhlbrigge 2012

Fuhlbrigge A, Peden D, Apter A, Boushey HA, Camargo CA Jr, Gern J, et al. Asthma outcomes: exacerbations. *The Journal of Allergy and Clinical Immunology* 2012;**129**(3 Suppl):S34–S48.

Gibson 1993

Gibson PG, Talbot PI, Hancock J, Hensley MJ. A prospective audit of asthma management following emergency asthma treatment at a teaching hospital. *Medical Journal of Australia* 1993;**158**:775–8.

GINA 2012

Global Initiative for Asthma. Pocket guide for asthma management and prevention (for adults and children older than 5 years). http://www.ginasthma.org/local/uploads/files/GINA_Pocket2013_May15.pdf (accessed 5 November 2013).

Higgins 2011

Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.

Kandane-Rathayake 2009

Kandane-Rathnayake RK, Matheson MC, Simpson JA, Tang MLK, Johns DP, Mészáros D, et al. Adherence to asthma management guidelines by middle-aged adults with current asthma. *Thorax* 2009;**64**(12):1025–31.

Krishnan 2006

Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. *American Journal of Respiratory and Critical Care Medicine* 2006;**174** (6):633–8.

Liu 2013

Liu Y, Zhang S, Li DW, Jiang S-J. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. *PLoS One* 2013; Vol. 8, issue 3:e59872. [DOI: 10.1371/journal.pone.0059872]

Masoli 2004

Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. *Allergy* 2004;**59**:469–78.

NHS 2011

Health and Social Care Information Centre. Hospital Episode Statistics. www.hesonline.nhs.uk (accessed 10 December 2012).

NIH 2007

National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (EPR 3). www.nhlbi.nih.gov/guidelines/asthma/ (accessed 10 December 2012).

Patel 2008

Patel S, Jarvelin MR, Little M. Systematic review of worldwide variations of the prevalence of wheezing symptoms in children. *Environmental Health* 2009;**7**:57. [DOI: doi.10.1186/1476-069X-7-57]

RevMan [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.

WHO 2007

Cruz AA, Mantzouranis E, Matricardi PM, Minelli E, Ait-Khaled N, Bateman ED, et al. In: Bousquet N, Khaltaev N editor(s). *Global Surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach*. Geneva: World Health Organization, 2007.

WHO 2011

World Health Organization. Health topics: asthma. www.who.int/topics/asthma/en/ (accessed 13 September 2011).

Wu 2007

Wu F, Takaro TK. Childhood asthma and environmental interventions. *Environmental Health Perspectives* 2007;**115** (6):971–5.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

Buttner 2003

Methods	Randomised, placebo-controlled, parallel-group trial
Participants	Reported as: "Seven male and 12 female patients with mild or moderate asthma, aged 20-59 yrs (mean 41 yrs), with duration of disease between 1-32 yrs (mean 11 yrs) were investigated. For inclusion, FEV ₁ had to be from 50 to 80% of predicted at baseline, with a reversibility of at least 12%. None of the patients suffered from clinical exacerbation, and all patients were on a stable daily dose of up to 1000 mcg beclomethasone dipropionate or a corresponding dose of other inhaled corticosteroids for at least 6 weeks prior to the study. As a symptom reliever salbutamol was allowed if needed. The detailed clinical characterisation of patients revealed no significant difference between the study groups." 5 participants allocated to receive mepolizumab 750 mg, 7 to receive mepolizumab 250 mg and 7 to receive placebo
Interventions	1 month run-in period to ensure stable disease 3 intravenous doses of either mepolizumab (750 mg), mepolizumab (250 mg) or placebo every 4 weeks with a follow-up period of 3 months
Outcomes	Peripheral blood leukocytes, qualitative and quantitative distribution of eosinophils and lymphocyte subpopulations, frequencies of IL-2, -3, -4, -5, -10, -13, interferon-c-producing CD4 T-cells and serum eosinophil cationic protein (ECP) levels
Notes	6-month multicentre trial in Germany Supported in part by SmithKline Beecham, Harlow, UK

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not reported
Allocation concealment (selection bias)	Unclear risk	Method of randomisation not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as double blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Reported as double blind
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Appears to be unreported

Selective reporting (reporting bias)	Low risk	No apparent indication of reporting bias
--------------------------------------	----------	--

Flood-Page 2003

Methods	2-centre, double-blind, placebo-controlled, parallel-group study
Participants	<p>Reported as: "Twenty-four people with mild asthma, with a FEV₁ of 70% or more of predicted. Participants were within an 18- to 55-year-old age range. All were atopic (defined by a positive skin prick test to one or more aeroallergen), and all were well controlled with short-acting 2-agonists, without corticosteroids or other anti-inflammatory drugs in the preceding 8 weeks</p> <p>All participants had a clear history of asthma, demonstrated airway hyperresponsiveness with a PC₂₀ to histamine of 4.0 mg/mL or less. All were nonsmokers. Eleven participants received mepolizumab and 13 received placebo."</p> <ul style="list-style-type: none"> • Age: mepolizumab, median 31 years (range 20 to 53); placebo, median 30 years (range 20 to 52) • Males: mepolizumab, 9; placebo, 8 • Baseline morning PEFr, L/min: mepolizumab, median 433 (range 358 to 585); placebo, median 459.5 (range 368 to 490) • Baseline FEV₁, L/s: mepolizumab, median 3.05 (range 2.55 to 4.85); placebo, median 3.1 (range 1.8 to 5.25) • Baseline FEV₁, % predicted: mepolizumab, median 87.0 (range 71 to 109); placebo, median 80.0 (range 71 to 106)
Interventions	3 Intravenous doses of either 750 mg of mepolizumab or placebo over 20 weeks (at weeks 0, 4 and 8)
Outcomes	Airway eosinophils, bone marrow eosinophils, blood eosinophils, airway hyperresponsiveness, FEV ₁ and PEFr
Notes	20-week study conducted at the Royal Brompton and London Chest Hospitals, London UK Supported by GlaxoSmithKline.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not reported
Allocation concealment (selection bias)	Unclear risk	Method of randomisation not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as double blind

Flood-Page 2003 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Reported as double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All 24 volunteers completed the study without reporting adverse events or asthma exacerbations
Selective reporting (reporting bias)	Low risk	No apparent indication of reporting bias

Flood-Page 2007

Methods	Multicentre, randomised, double-blind, placebo-controlled trial
Participants	<p>Reported as: "Enrolled into the study were nonsmoking participants, aged 18-55 years, with asthma managed with inhaled corticosteroids (maximum dose of beclomethasone dipropionate (BDP) or equivalent, 1000 mcg/d). The FEV₁ had to be at least 50% and not more than 80% of the predicted value for age, sex, and height with documented beta₂-agonist reversibility of at least 12% after administration of 180 mcg of albuterol (salbutamol). The daily symptom score had to be at least 4 (maximum score, 12) during the 7 days preceding the baseline assessment. The principal exclusion criteria to ensure asthma stability and safety before dosing were as follows: an absolute FEV₁ value measured at randomisation (visit 3) that had changed by more than 20% from the value determined at a baseline signs-and-symptoms visit 2 weeks before dosing (visit 2); an upper respiratory tract infection in the 2 weeks before the first visit; use of oral corticosteroids in the 4 weeks before the first visit; or poorly controlled asthma, defined as hospitalisation or an emergency room visit for the treatment of asthma in the 6 weeks before the first visit."</p> <ul style="list-style-type: none"> • 116 allocated to receive mepolizumab 750 mg (112 completed), 120 to receive mepolizumab 250 mg (110 completed) and 126 to receive placebo (119 completed) • Age (standard deviation (SD)): mepolizumab 750 mg, mean 36.3 years (±10.4), mepolizumab 250 mg, mean 35.8 years (± 40); placebo, mean 36.8 years (± 10) • Males: mepolizumab 750 mg, 60; mepolizumab 250 mg, 52; placebo, 48 • Baseline ICS (beclomethasone) dose (mcg/d) (SD): mepolizumab 750 mg, mean 710 (± 381); mepolizumab 250 mg, mean 720 (± 448); placebo, mean 740 (± 486) • Baseline morning mean PEF_R (L/min) (SD): mepolizumab 750 mg, 375.7 (± 88.8); mepolizumab 250 mg 357.9 (± 90.6); placebo, 359.4 (± 90.4) • Baseline mean FEV₁ (L) (SD): mepolizumab 750 mg, 2.51 (±0.58); mepolizumab 250 mg, 2.46 (± 0.56); placebo, 2.39 (± 0.59) • Baseline mean (SD) FEV₁, % predicted: mepolizumab 750 mg, 68.3% (± 8.8%); mepolizumab 250 mg, 68.4% (± 9.6%); placebo, 68.4% (± 8.7%) • Baseline mean (SD) FEV₁ reversibility: mepolizumab 750 mg, 24.5% (± 11.6%); mepolizumab 250 mg, 24.6% (± 12.1%); placebo, 25.1% (± 11.6%)
Interventions	<p>4-week run-in period to ensure stable disease 3 intravenous doses of mepolizumab (750 mg), mepolizumab (250 mg) or placebo (at weeks 0, 4 and 8)</p>

Outcomes	Reported as: “The primary efficacy variable was the change from baseline in domiciliary morning peak expiratory flow rate (PEFR) recorded at weeks 12 and 20. This was recorded as the mean PEFR over the 7 days preceding the treatment period (baseline value) and preceding weeks 12 and 20. The secondary efficacy variables were the changes from baseline of FEV ₁ , asthma summary symptom scores (the total of the daytime asthma, nighttime asthma, and morning asthma scores), use of rescue medication such as albuterol (salbutamol), quality of life scores, asthma exacerbation rates, and eosinophil counts in blood and sputum.”	
Notes	20-week multicentre trial at 55 centres in 5 countries (France, Germany, Netherlands, the UK, and the USA) Supported by GlaxoSmithKline.	
Risk of bias		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not reported
Allocation concealment (selection bias)	Unclear risk	Method of randomisation not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as double blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Reported as double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reported as: “Of the 362 patients randomised into the study, a total of 21 patients (5.8%) were withdrawn. The percentage of patients completing the study was high for all treatment arms. The most common reason for withdrawal during the study was adverse experience (n=10; 2.8%). The percentage of patients who were withdrawn because of adverse experiences was higher among patients receiving placebo (4.0%) and mepolizumab at 250 mg (3.3%) compared with patients receiving mepolizumab at 750 mg (0.9%). A total of 37 patients were randomised to the induced sputum arm of the study, and 3 patients were subsequently withdrawn.”

Selective reporting (reporting bias)	High risk	No significant difference in HRQoL and did not provide any data
--------------------------------------	-----------	---

Haldar 2009

Methods	Randomised, double-blind, placebo-controlled, parallel-group trial	
Participants	<p>Participants had refractory eosinophilic asthma and a history of recurrent severe exacerbations</p> <p>Reported as: "Inclusion criteria were a diagnosis of refractory asthma according to American Thoracic Society criteria, a sputum eosinophil percentage of more than 3% on at least one occasion in the previous 2 years despite high-dose corticosteroid treatment, and at least two exacerbations requiring rescue prednisolone treatment in the previous 12 months. Additional criteria for inclusion were stable treatment requirements and an absence of exacerbations for more than 6 weeks before enrolment in the study. Exclusion criteria were current smoking, serologic evidence of a parasitic infection, a serious coexisting illness, the possibility of conception, and poor adherence to treatment."</p> <ul style="list-style-type: none"> • Age: mepolizumab, mean 48 (range from 21 to 63); placebo, mean 50 (range from 24 to 72) • Males: mepolizumab, 14; placebo, 18 • Baseline mean (SD) FEV₁, % predicted after bronchodilator use: mepolizumab, 78.1% (± 20.9%); placebo, 77.6% (± 24.1%) • Baseline mean (SD) FEV₁/FVC ratio: mepolizumab, 72.2% (± 9.6%), placebo, 67.7% (± 13.5%) • 29 allocated to receive mepolizumab 750 mg, 32 to receive placebo 	
Interventions	Intravenous mepolizumab (750 mg) versus matched placebo (150 mL of 0.9% saline) at monthly intervals for 1 year	
Outcomes	<p>Reported as: "[P]rimary outcome measure was the number of severe exacerbations per subject during the 50-week treatment phase. Secondary outcomes included a change in asthma symptoms, scores on the Asthma Quality of Life Questionnaire (AQLQ, in which scores range from 1 to 7, with lower values indicating more severe impairment and a change of 0.5 unit considered to be clinically important), forced expiratory volume in 1 second (FEV₁) after use of a bronchodilator, airway hyperresponsiveness, and eosinophil counts in the blood and sputum."</p>	
Notes	Single centre trial conducted at Institute for Lung Health, Leicester, UK Supported by GlaxoSmithKline	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Reported as: "Stratified randomisation with use of the minimisation method, which was performed by

Haldar 2009 (Continued)

		an independent clinician. Participants were randomly assigned with the use of the minimisation method to receive 12 infusions of either 750 mg of mepolizumab delivered intravenously or matched placebo (150 mL of 0.9% saline) at monthly intervals between visits 3 and 14. The criteria used for minimisation were the frequency of exacerbations in the previous 12 months, the baseline eosinophil count in the sputum and the number of participants taking oral corticosteroids.”
Allocation concealment (selection bias)	Unclear risk	Details not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as double blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Reported as double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reported as: “A total of 61 of the 63 participants (one required and operation and one withdrew consent) who were screened started treatment and constituted the modified intention-to-treat population. Thirty-two participants were randomly assigned to receive placebo. Overall, 94.9% of treatment visits were completed. Participants who withdrew completed a mean of 4.6 treatment visits (38.3%).”
Selective reporting (reporting bias)	Low risk	No apparent indication of reporting bias

Leckie 2000

Methods	Randomised, double-blind, placebo-controlled trial
Participants	Participants with mild allergic asthma Reported as: “24 non-smoking men (mean age 27, range 18-45 years) with mild allergic asthma (as defined by the American Thoracic Society) and a history of episodic wheeze and shortness of breath. The patients were atopic, as defined by positive skin tests in response to common airborne allergens (<i>Der-matophagoides pteronyssinus</i> , mixed grass pollen and cat hair) and were maintained on short-acting inhaled 2-agonist treatment as required. Patients had neither worsening asthma nor a respiratory infection in

	<p>the preceding 6 weeks. FEV₁ at baseline was at least 70% of the predicted value and there was a documented airway hyperresponsiveness to histamine, with a provocation concentration causing a 20% reduction in FEV₁ (PC₂₀) < 8 mg/mL. Patients had documented early and late asthmatic responses (defined as a 15% reduction in FEV₁ on at least three occasions between 4 and 10 h after allergen) to inhaled incremental allergen challenge between 3 and 6 weeks before the study treatment was given.”</p> <ul style="list-style-type: none"> • Mean age (SD): mepolizumab 10 mg/kg, 28.0 years (± 4.3); mepolizumab 2.5 mg/kg, 30.0 (± 8); placebo, 25.6 (± 4.1) • Males: mepolizumab 10 mg/kg, 8; mepolizumab 2.5 mg/kg, 8; placebo, 8 • Baseline mean (SD) FEV₁, % predicted: mepolizumab 10 mg/kg, 82.0% (± 7.0%); mepolizumab 2.5 mg/kg, 90.3% (± 10.4%); placebo, 93.0% (± 9.6%) • 8 allocated to receive mepolizumab 10 mg/kg (8 completed), 8 allocated to receive mepolizumab 2.5 mg/kg (7 completed) and 8 to receive placebo (8 completed)
Interventions	Mepolizumab 10 mg/kg versus mepolizumab 2.5 mg/kg versus placebo
Outcomes	Blood eosinophils, sputum eosinophils, histamine PC ₂₀ (mg/mL), late asthmatic reaction (maximum % fall in FEV ₁)
Notes	16 week study conducted at 3 centres: Imperial College London, Southampton University and University of Amsterdam Supported by SmithKline Beecham, UK

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not reported
Allocation concealment (selection bias)	Unclear risk	Method of randomisation not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study reported as double blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Study reported as double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	1 subject lost to follow-up, all other data appears to be reported
Selective reporting (reporting bias)	Low risk	No apparent indication of reporting bias

Methods	Randomised, double-blind, placebo-controlled trial
Participants	<p>Inclusion criteria: Adult patients, aged 18 to 70 years, who were followed as outpatients and who required a minimum dose of prednisone treatment (in addition to high-dose inhaled steroid treatment) to prevent frequent exacerbations associated with induced sputum eosinophilia. Patients were enrolled if, at screening and baseline visits, they demonstrated sputum eosinophilia and symptoms. The symptoms could affect activity and sleep but should not have been severe enough to be of concern to the treating physician. Both FEV₁ (after appropriately withholding bronchodilators before and after inhaled salbutamol 200 mcg) and methacholine PC₂₀ were measured, but these did not need to be abnormal since the prednisone was required for the control of eosinophilic bronchitis and any clinical consequences of this, and because bronchitis can occur without these features of asthma. On the same doses of corticosteroids for a least one month</p> <p>Exclusion criteria: pregnancy, breastfeeding or lack of effective contraception in females of childbearing potential or females who are postmenopausal < 1 year. Baseline predicted FEV₁ before bronchodilator of 40% or less. This lower FEV₁ was acceptable since chronic airflow limitation, secondary to the eosinophilic bronchitis or asthma, is not an exclusion criterion. Neither is current or ex-cigarette smoking provided that the best FEV₁ in these patients was >60% predicted normal, or the best FEV₁/VC ratio was >60% in the previous two years. Exposure to a relevant seasonal environmental allergen, known to worsen asthma control, during the study period. Respiratory tract infection in the 4 weeks before the baseline visit. Clinical exacerbation requiring extra prednisone treatment in the 4 weeks before visit 1. Other cardiac, pulmonary, renal or systemic diseases that in the investigator's opinion could interfere with the study results or compromise participants' safety. Previous participation in any study using anti-monoclonal drug</p> <p>9 patients were assigned to receive mepolizumab (administered in 5 monthly infusions of 750 mg each) and 11 patients to receive placebo</p> <ul style="list-style-type: none"> • Mean age (SD): mepolizumab, 56.4 years (± 10.9); placebo, 58.2 years (± 7) • Male: mepolizumab, 4; placebo, 8 • Mean (SD) duration of symptoms: mepolizumab, 13.3 years (± 10.3); placebo, 12.5 years (± 9.5) • Baseline mean (SD) FEV₁ previous minimum (L): mepolizumab, 1.4 (± 0.6); placebo, 1.6 (± 0.5) • Baseline mean (SD) FEV₁, % predicted: mepolizumab, 48% (± 17); placebo, 52% (± 13%)
Interventions	5 intravenous doses of either mepolizumab (750 mg) or placebo (administered in 5 monthly infusions)
Outcomes	<p>Primary outcome: The prednisone-sparing effect of mepolizumab versus placebo as indicated by the absolute and percentage dose reduction possible without a clinical exacerbation (as measured by the JACQ in patients with asthma or by Likert symptom scores + FEV₁ in patients with eosinophilic bronchitis without asthma).</p> <p>Secondary outcome measures: The prednisone-sparing effect of mepolizumab or placebo as indicated by the absolute and percentage dose reduction possible without a clinical exacerbation, as measured by;</p> <ul style="list-style-type: none"> • % sputum eosinophils; • FEV₁ % predicted and methacholine PC₂₀;

	<ul style="list-style-type: none"> • blood eosinophils; • amount of rescue salbutamol used; • time to exacerbation. 	
Notes	26-week trial at Firestone Institute for Respiratory Health, St. Joseph's Healthcare and Department of Medicine, McMaster University, Hamilton, ON, Canada Supported by an unrestricted educational grant from GlaxoSmithKline	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation codes stratified patients into two groups of 10 according to the daily dose of prednisone they were receiving at the time of enrolment (< 10 mg or ≥ 10 mg). Within each of the two groups, patients were equally divided among those receiving mepolizumab and those receiving placebo. When either group was filled, no additional patients were recruited for that group
Allocation concealment (selection bias)	Low risk	Randomisation codes were held by the pharmacy department, whose members were unaware of clinical details in the study groups
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as double blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Reported as double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Two of the patients were included in the study in error and were therefore excluded from some but not all of the analyses before the randomisation code was broken
Selective reporting (reporting bias)	Low risk	No apparent indication of reporting bias

Methods	Randomised, double-blind, double-dummy, phase 3 study
Participants	<p>576 patients with recurrent asthma exacerbations and evidence of eosinophilic inflammation despite high doses of inhaled glucocorticoids to one of three study groups</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • Able to give written informed consent prior to participation in the study • At least 12 years of age at visit 1 with a minimum weight of 45kg • A well-documented requirement for regular treatment with high dose ICS in the 12 months prior to visit 1, with or without maintenance oral corticosteroids (OCS) <ul style="list-style-type: none"> • Current treatment with an additional controller medication, besides ICS, for at least 3 months, or a documented failure in the past 12 months of an additional controller medication for at least 3 successive months • Prior documentation of eosinophilic asthma or high likelihood of eosinophilic asthma <ul style="list-style-type: none"> • At visit 1, a pre-bronchodilator FEV₁ < 80% (for participants ≥ 18 years of age), a pre-bronchodilator FEV₁ < 90% or FEV₁/FVC ratio < 0.8 (for participants 12 to 17 years of age) • Previously confirmed history of two or more exacerbations requiring treatment with systemic corticosteroids • Male or eligible female (females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control) • French participants will be included only if affiliated to or a beneficiary of a social security category <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • Current smokers or former smokers with a smoking history of ≥ 10 pack-years • Presence of a known pre-existing, clinically important lung condition other than asthma <ul style="list-style-type: none"> • A current malignancy or previous history of malignancy in previous 12 months • Known, pre-existing, unstable liver disease cirrhosis and known biliary abnormalities • Known, pre-existing severe or clinically significant cardiovascular disease • Known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment • Participants with any eosinophilic diseases • QTc(F)^a ≥ 450 ms or QTc(F) ≥ 480 ms • A history of alcohol/substance abuse • Known immunodeficiency • Administration of omalizumab within 130 days of visit 1 or any other monoclonal antibody to treat inflammatory disease within 5 half-lives of visit 1 <ul style="list-style-type: none"> • Treatment with an investigational drug within the previous 30 days or 5 terminal phase half-lives of the drug, whichever is longer • Allergy/intolerance to a monoclonal antibody or biologic therapy • Pregnant or breastfeeding • Known evidence of lack of adherence to controller medications, inability to follow physician's recommendations, or both • Previous participation in any study with mepolizumab and administration of investigational product (including placebo)

Ortega 2014 (Continued)

Interventions	Mepolizumab in a 75 mg intravenous dose versus mepolizumab in a 100 mg subcutaneous dose versus placebo every 4 weeks for 32 weeks
Outcomes	<p>Primary outcome:</p> <ul style="list-style-type: none"> Number of clinically significant exacerbations of asthma per year <p>Secondary outcomes:</p> <ul style="list-style-type: none"> Number of clinically significant exacerbations requiring hospitalisation (including intubation and admittance to an intensive care unit) or ED visits per year Mean change from baseline in clinic pre-bronchodilator FEV₁ at week 32 Mean change from baseline in the SGRQ total score at week 32
Notes	32-week treatment intervention, with 1 to 6 weeks run-in and 8-week followup. Conducted in Baltimore, Middlesex, Ghent, Vancouver, Parma, Marseille and Paris

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Centralised computer-generated permuted block schedule
Allocation concealment (selection bias)	Low risk	Treatment allocations will be concealed via the RandAll system
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Mepolizumab and placebo were identical in appearance and were administered by a staff member who was unaware of the study group assignments
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The study drugs were prepared by staff members who were aware of the study group assignments but were not involved in study assessments
Incomplete outcome data (attrition bias) All outcomes	Low risk	6% (placebo), 8% (IV), 5% (SC) did not complete the study
Selective reporting (reporting bias)	Low risk	All outcome measures reported

Pavord 2012

Methods	Multicentre, double-blind, placebo-controlled trial
Participants	<p>People with severe asthma despite receiving high doses of standard asthma medications</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> Male or female Aged 12 to 65 years inclusive

- Minimum weight 45 kg
 - Clinical features of severe refractory asthma
 - Well-documented requirement for high dose ICS (i.e. ≥ 880 mcg/day fluticasone propionate or equivalent daily) for at least 12 months
 - Use of additional controller medication in addition to high dose ICS for at least 12 months
 - Persistent airflow obstruction indicated by a pre-bronchodilator FEV₁ < 80% predicted at visit 1 or 2 or peak flow diurnal variability of > 20% on 3 or more days during the run-in
 - Airway inflammation likely to be eosinophilic in nature, demonstrated by either raised peripheral blood eosinophils ($\geq 300/\mu\text{L}$), sputum eosinophils ($\geq 3\%$), exhaled nitric oxide (≥ 50 ppb) or prompt deterioration of asthma control following a $\leq 25\%$ reduction in regular maintenance dose of ICS or OCS
 - History of ≥ 2 exacerbations requiring systemic corticosteroids in the previous 12 months
 - Evidence of asthma documented by airway reversibility, airway hyperresponsiveness or airflow variability
 - ECG assessment demonstrating QTc < 450 ms or QTc < 480 ms for patients with bundle branch block
 - Liver function tests on surrogate markers for liver disease, demonstrating ALT < 2 x ULN, AST < 2 x ULN, Alk Phos ≤ 1.5 x ULN, bilirubin ≤ 1.5 x ULN
 - Female of non-child-bearing potential or child-bearing potential with a negative pregnancy test at screening and prepared to use an acceptable method of contraception
 - Able to give written informed consent
 - Able to read, comprehend and write at a sufficient level to complete study materials
- Exclusion Criteria:
- Current smokers or smoking history of ≥ 10 pack years
 - Clinically important lung condition other than asthma
 - Diagnosis or suspicion of malignancy
 - Unstable liver disease
 - Churg-Strauss syndrome
 - Use of methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine or any experimental anti-inflammatory therapy within 3 months of screening
 - Administration of omalizumab (Xolair) or any other biological agent for the treatment of inflammatory disease within 6 months of visit 1
 - Regular use of OCS or systemic corticosteroids for diseases other than asthma within 12 months; any intra-articular, short-acting intramuscular corticosteroid within 1 month; or intramuscular, long-acting depot corticosteroid within 3 months
 - Allergy/intolerance to the excipients in the mepolizumab formulation
 - Administration of any investigational drug in previous 30 days or 5 terminal half-lives, whichever is longer
 - Pregnant, breastfeeding or planning to become pregnant
 - Clinically significant disease which is uncontrolled with standard treatment
 - History of alcohol misuse or substance abuse
 - Parasitic infestation within previous 6 months
 - Known immunodeficiency
 - Unable to follow instructions, use the electronic diary or peak flow meter

	<ul style="list-style-type: none"> • Known evidence of lack of adherence to controller medications, inability to follow physician's recommendations, or both • Previous participation in a study of mepolizumab and received study medication within 90 days • 621 patients were randomised: 156 were assigned to 750 mg mepolizumab, 152 to 250 mg mepolizumab, 154 to 75 mg mepolizumab, and 159 to placebo
Interventions	13 total intravenous infusions of mepolizumab (750 mg), mepolizumab (250 mg), mepolizumab (75 mg) or placebo given every 4 weeks
Outcomes	<p>Primary outcome:</p> <ul style="list-style-type: none"> • Frequency of clinically significant exacerbations of asthma <p>Secondary outcomes:</p> <ul style="list-style-type: none"> • Time to first clinically significant exacerbation requiring oral or systemic corticosteroids, hospitalisation, and/or ED visits • Frequency of exacerbations requiring hospitalisation (including intubation and admittance to an ICU) or ED visits • Time to first exacerbation requiring hospitalisation or ED visit • Frequency of investigator-defined exacerbations • Time to first investigator-defined exacerbation • Mean change from baseline in clinic pre-bronchodilator FEV₁ over the 52-week treatment period • Mean change from baseline in clinic post-bronchodilator FEV₁ over the 52-week treatment period • Mean change from baseline in ACQ score
Notes	52-week study conducted at 81 centres in 13 countries (Argentina, Australia, Canada, Chile, France, Germany, South Korea, Poland, Romania, Russia, Ukraine, the UK and the USA) Supported by GlaxoSmithKline

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Central telephone-based system and computer-generated randomly permuted block schedule stratified by whether treatment with oral corticosteroids was required
Allocation concealment (selection bias)	Low risk	Mepolizumab and placebo were prepared by unmasked site staff who were not involved in study assessments
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Mepolizumab and placebo were prepared by unmasked site staff who were not involved in study assessments. Both treatments were identical in appearance and were given to patients by a masked member

		of the site staff
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Data analysts were masked to treatment allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients accounted for with information on reasons for having withdrawn. Some patients not included in results due to 'poor efficacy'
Selective reporting (reporting bias)	Low risk	No apparent indication of reporting bias

ACQ: Asthma Control Questionnaire; **ALT:** alanine aminotransferase; **Alk Phos:** alkaline phosphatase; **AQLQ:** Asthma Quality of Life Questionnaire; **AST:** aspartate aminotransferase; **ECP:** eosinophil cationic protein; **ED:** emergency department; **FEV₁:** Forced expiratory volume in 1 second; **FVC:** forced vital capacity; **HRQoL:** health-related quality of life; **ICS:** inhaled corticosteroid; **IL:** interleukin; **IV:** intravenous; **JACQ:** Juniper Asthma Control Questionnaire; **OCS:** oral corticosteroids; **PC₂₀:** histamine provocative concentration causing a 20% drop in FEV₁; **PEFR:** peak expiratory flow rate; **SC:** subcutaneous; **SD:** standard deviation; **SGRQ:** St. George's Respiratory Questionnaire; **ULN:** Upper Limit of Normal; **VC:** vital capacity.

^a**QTc(F):** a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle, corrected for the heart rate using Fredericia's formula.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Alvarez-Cuesta 1994	Study does not include mepolizumab
Armentia 1992	Study does not include mepolizumab
Ayres 2004	Study does not include mepolizumab
Bel 2014	Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria
Berger 2003	Study does not include mepolizumab
Blanken 2012	Study does not include mepolizumab
Blanken 2013	Study does not include mepolizumab
Boulet 1997	Study does not include mepolizumab
Bousquet 2004	Study does not include mepolizumab

(Continued)

Bousquet 2011	Study does not include mepolizumab
Brown 2007	Study does not include mepolizumab
Bryant 1975	Study does not include mepolizumab
Bryant 1975a	Study does not include mepolizumab
Buhl 2000a	Study does not include mepolizumab
Buhl 2000b	Study does not include mepolizumab
Buhl 2002	Study does not include mepolizumab
Bush 1985	Study does not include mepolizumab
Busse 2001	Study does not include mepolizumab
Busse 2008	Study does not include mepolizumab
Caffarelli 2000	Study does not include mepolizumab
Castro 2010	Does not include Mepolizumab
Castro 2011	Does not include Mepolizumab
Chandra 1989	Study does not include mepolizumab
Chervinsky 2003	Study does not include mepolizumab
Clavel 1998	Study does not include mepolizumab
Corren 2003	Study does not include mepolizumab
Corren 2010	Study does not include mepolizumab
Cullell-Young 2002	Study does not include mepolizumab
De Boever 2014	Study does not include mepolizumab
Djukanovic 2004	Study does not include mepolizumab
Ebner 1989	Study does not include mepolizumab
Eckman 2010	Study does not include mepolizumab

(Continued)

El-Nawawy 2000	Study does not include mepolizumab
Fahy 1997	Study does not include mepolizumab
Fahy 1999	Study does not include mepolizumab
Finn 2003	Study does not include mepolizumab
Frew 1998	Study does not include mepolizumab
Garcia 2013	Study does not include mepolizumab
Gauvreau 2011	Study does not include mepolizumab
Gauvreau 2014a	Study does not include mepolizumab
Gauvreau 2014b	Study does not include mepolizumab
Gauvreau 2014c	Study does not include mepolizumab
Gevaert 2013	Study does not include mepolizumab
Gordon 1972	Study does not include mepolizumab
Greenberg 1991	Study does not include mepolizumab
Han 2009	Study does not include mepolizumab
Hanania 2011	Study does not include mepolizumab
Hanania 2013	Study does not include mepolizumab
Hanania 2014	Study does not include mepolizumab
Hill 1982	Study does not include mepolizumab
Hodsman 2013	Study does not include mepolizumab
Holgate 2004	Study does not include mepolizumab
Hoshino 2012	Study does not include mepolizumab
Humbert 2005	Study does not include mepolizumab
Humbert 2008	Study does not include mepolizumab

(Continued)

Humbert 2009	Study does not include mepolizumab
Jacquemin 1995	Study does not include mepolizumab
Jutel 2005	Study does not include mepolizumab
Kang 1988	Study does not include mepolizumab
Kips 2003	Study does not include mepolizumab
Kon 2001	Study does not include mepolizumab
Kopp 2009	Study does not include mepolizumab
Kopp 2013	Study does not include mepolizumab
Kulus 2010	Study does not include mepolizumab
Lanier 2003	Study does not include mepolizumab
Lanier 2009	Study does not include mepolizumab
Lavolette 2013	Study does not include mepolizumab
Leynadier 2004	Study does not include mepolizumab
Lizaso 2008	Study does not include mepolizumab
Massanari 2009	Study does not include mepolizumab
Massanari 2010	Study does not include mepolizumab
Mathur 2011	Study does not include Mepolizumab
Metzger 1998	Study does not include mepolizumab
Milgrom 1999	Study does not include mepolizumab
Milgrom 2001	Study does not include mepolizumab
Modlin 1977	Study does not include mepolizumab
Moss 1987	Study does not include mepolizumab
Nair 2010	Study does not include mepolizumab

(Continued)

NCT00802438	Non randomised study
NCT01366521	Phase 2 study comparing three doses of Mepolizumab. This trial does not have a placebo arm
NCT01471327	Focus of study was on tolerability, pharmacokinetics and pharmacodynamics of single dose SB-240563 administered intravenously to Japanese healthy male subjects. Patients with asthma were not included in the study
NCT01691859	This study does not include a placebo group. Multi-centre, open-label, long term safety study with total sample receiving 100 milligrams (mg) mepolizumab administered subcutaneously (no control group)
NCT01842607	This study does not include a placebo group. Multi-centre, open-label, long term safety study with total sample receiving 100 milligrams (mg) mepolizumab administered subcutaneously (no control group)
NCT02135692	This study does not include a placebo group. Multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma
NCT02293265	Study does not include mepolizumab (aim of study is to provide a 'reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab'),
Niven 2008	Study does not include mepolizumab
Noga 2003	Study does not include mepolizumab
Noga 2008	Study does not include mepolizumab
Noonan 2013	Study does not include mepolizumab
Oba 2004	Study does not include mepolizumab
Oh 2013	Study does not include mepolizumab
Ohashi 1997	Study does not include mepolizumab
Ohman 1984	Study does not include mepolizumab
Ohta 2009	Study does not include mepolizumab
Ong 2005	Study does not include mepolizumab
Parker 2010	Study does not include mepolizumab
Pauli 1984	Study does not include mepolizumab
Piper 2013	Study does not include mepolizumab

(Continued)

Prieto 2006	Study does not include mepolizumab
Pui 2010	Study does not include mepolizumab
Rose 2009	Study does not include mepolizumab
Sakamoto 1984	Study does not include mepolizumab
Scheerens 2011	Study does not include mepolizumab
Scheerens 2014	Study does not include mepolizumab
Siergiejko 2011	Study does not include mepolizumab
Silk 1998	Study does not include mepolizumab
Silkoff 2004	Study does not include mepolizumab
Simoes 2007	Study does not include mepolizumab
Singh 2010	Study does not include mepolizumab
Slavin 2009	Study does not include mepolizumab
Soler 2001	Study does not include mepolizumab
Sorkness 2013	Does not include Mepolizumab
Sthoeger 2007	Study does not include mepolizumab
Sugaya 1994	Study does not include mepolizumab
Swanson 2014	Study does not include mepolizumab
Szymaniak 1998	Study does not include mepolizumab
Tanaka 1993	Study does not include mepolizumab
Terr 1969	Study does not include mepolizumab
Van Rensen 2009	Study does not include mepolizumab
Vignola 2004	Study does not include mepolizumab
Wark 2003	Study does not include mepolizumab

(Continued)

Wenzel 2009	Study does not include mepolizumab
Wenzel 2013	Study does not include mepolizumab
Zetterstrom 1972	Study does not include mepolizumab
Zhu 2013	Study does not include mepolizumab
Zielen 2013	Study does not include mepolizumab

Characteristics of ongoing studies [ordered by study ID]

NCT01520051 2012

Trial name or title	Mepolizumab treatment for rhinovirus-induced asthma exacerbations (MATERIAL)
Methods	Randomised double blind trial
Participants	<p>Mild allergic asthma patients with viral airway infections</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none">• Age: from 18 to 50 years• History of episodic chest tightness and wheezing• Intermittent or mild persistent asthma according to the criteria of the Global Initiative for Asthma• Non-smoking or stopped smoking more than 12 months ago and ≤ 5 pack-years• Clinically stable, no history of exacerbations within 6 weeks prior to the study• Steroid-naïve or those not currently on corticosteroids and who have not taken any corticosteroids by any dosing routes within 2 weeks prior to the study. Occasional usage of inhaled short-acting beta₂-agonists as rescue medication is allowed, prior to and during the study• Baseline FEV₁ > 80% of predicted• Airway hyperresponsiveness, indicated by a positive acetyl-beta-methylcholine bromide (MeBr) challenge with PC₂₀ < 9.8 mg/mL• Positive skin prick test (SPT) to one or more of the 12 common aeroallergen extracts, defined as a wheal with an average diameter over 3 mm• No other clinically significant abnormality on medical history and clinical examination <p>Exclusion Criteria:</p> <ul style="list-style-type: none">• Presence of antibodies directed against RV16 in serum (titre > 4), measured at visit 1• History of clinical significant hypotensive episodes or symptoms of fainting, dizziness, or light-headedness• Women who are pregnant, lactating or who have a positive urine pregnancy test at visit 1• Chronic use of any other medication for treatment of lung disease other than short-acting beta₂-agonists• Participation in any clinical investigational drug treatment protocol in previous 3 months• Ongoing use of tobacco products of any kind or previous usage with ≥ 6 total pack-years• Concomitant disease or condition which could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or which would, in the opinion of the investigator, pose an unacceptable risk to the patient• People with young children (< 2 years)

NCT01520051 2012 (Continued)

Interventions	3 monthly intravenous infusions of 750 mg versus 3 monthly intravenous infusions with saline
Outcomes	<p>Primary outcome measures:</p> <ul style="list-style-type: none"> • FEV₁ 1 day prior and 6 days after RV16 challenge • Questionnaire to score asthma and common cold complaints during 14 days following viral infection <p>Secondary outcome measures:</p> <ul style="list-style-type: none"> • Viral load on day 6 after viral infection • Sputum eosinophils before and after mepolizumab infusion • Cell influx in bronchoalveolar lavage fluid 6 days after viral infection • Pro-inflammatory cytokines in bronchoalveolar lavage fluid 6 days after viral infection • Antibody production 6 weeks after infection
Starting date	January 2012
Contact information	Suzanne Bal, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Notes	

NCT02281318 2014

Trial name or title	A randomised, double-blind, placebo-controlled, parallel-group, multi-centre, 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control
Methods	Multicentre, placebo-controlled, double-blind, parallel-group study
Participants	People with severe eosinophilic asthma. Approximately 780 participants with severe eosinophilic asthma will be screened to ensure the randomisation of 544 participants (272 participants per treatment group) into the study
Interventions	Mepolizumab 100 mg subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment, versus placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
Outcomes	<p>Primary Outcome Measure:</p> <ul style="list-style-type: none"> • Mean change from baseline in St. George's Respiratory Questionnaire (SGRQ) score at week 24 <p>Secondary Outcome Measures:</p> <ul style="list-style-type: none"> • Mean change from baseline in clinic pre-bronchodilator FEV₁ at week 24 • Percentage of participants achieving a 4 point or greater reduction from baseline in SGRQ score at week 24 • Mean change from baseline in five-item Asthma Control Questionnaire (ACQ-5) score at week 24
Starting date	December 2014
Contact information	US GSK Clinical Trials Call Center: GSKClinicalSupportHD@gsk.com

NCT02281318 2014 (Continued)

Notes	Estimated primary completion date: 2016
-------	---

FEV₁ : Forced expiratory volume in 1 second; **PC₂₀** : histamine provocative concentration causing a 20% drop in FEV₁

DATA AND ANALYSES

Comparison 1. IV Mepolizumab versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Health-related quality of life (AQLQ)	2		Mean Difference (Random, 95% CI)	Subtotals only
1.1 AQLQ	2	677	Mean Difference (Random, 95% CI)	0.21 [-0.01, 0.44]
2 Health-related quality of life (SGRQ)	1		Mean Difference (Random, 95% CI)	Subtotals only
2.1 SGRQ	1		Mean Difference (Random, 95% CI)	-6.4 [-9.65, -3.15]
3 Rate of clinically significant exacerbations	2		Rate Ratio (Random, 95% CI)	Subtotals only
3.1 75 mg mepolizumab versus placebo	2	690	Rate Ratio (Random, 95% CI)	0.52 [0.43, 0.64]
3.2 250 mg mepolizumab versus placebo	1	307	Rate Ratio (Random, 95% CI)	0.61 [0.46, 0.81]
3.3 750 mg mepolizumab versus placebo	1	311	Rate Ratio (Random, 95% CI)	0.48 [0.36, 0.64]
4 Rate of exacerbations requiring admission	2		Rate Ratio (Random, 95% CI)	Subtotals only
4.1 75 mg mepolizumab versus placebo	2	690	Rate Ratio (Random, 95% CI)	0.61 [0.33, 1.13]
4.2 250 mg mepolizumab versus placebo	1	307	Rate Ratio (Random, 95% CI)	0.65 [0.31, 1.37]
4.3 750 mg mepolizumab versus placebo	1	311	Rate Ratio (Random, 95% CI)	0.37 [0.16, 0.86]
5 Rate of exacerbations requiring ED or admission	2		Rate Ratio (Random, 95% CI)	Subtotals only
5.1 75 mg mepolizumab versus placebo	2	690	Rate Ratio (Random, 95% CI)	0.52 [0.31, 0.87]
5.2 250 mg mepolizumab versus placebo	1	307	Rate Ratio (Random, 95% CI)	0.58 [0.30, 1.12]
5.3 750 mg mepolizumab versus placebo	1	311	Rate Ratio (Random, 95% CI)	0.52 [0.27, 1.02]
6 People with one or more exacerbations	4	467	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.34, 1.31]
7 Serious adverse events	5	1441	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.30, 0.80]
8 FEV1 (litres)	1		Mean Difference (Random, 95% CI)	Subtotals only
8.1 250 mg mepolizumab versus placebo	1	246	Mean Difference (Random, 95% CI)	-0.03 [-0.13, 0.07]
8.2 750 mg mepolizumab versus placebo	1	242	Mean Difference (Random, 95% CI)	0.02 [-0.10, 0.14]
9 PEFr (L/min)	1		Mean Difference (Random, 95% CI)	Subtotals only
9.1 250 mg mepolizumab versus placebo	1	246	Mean Difference (Random, 95% CI)	13.49 [0.71, 26.27]

9.2 750 mg mepolizumab versus placebo	1	242	Mean Difference (Random, 95% CI)	3.42 [-9.40, 16.24]
10 Post bronchodilator FEV ₁ (L)	3		Mean Difference (Random, 95% CI)	Totals not selected
10.1 6 weeks	1		Mean Difference (Random, 95% CI)	0.0 [0.0, 0.0]
10.2 32 weeks	1		Mean Difference (Random, 95% CI)	0.0 [0.0, 0.0]
10.3 1 year	1		Mean Difference (Random, 95% CI)	0.0 [0.0, 0.0]
11 Percentage predicted FEV ₁ after bronchodilation	1		Mean Difference (Random, 95% CI)	Totals not selected
11.1 6 weeks	1		Mean Difference (Random, 95% CI)	0.0 [0.0, 0.0]
12 Pre-bronchodilator FEV ₁ (L) at week 32	1		Mean Difference (Random, 95% CI)	Totals not selected
12.1 75 mg mepolizumab versus placebo	1		Mean Difference (Random, 95% CI)	0.0 [0.0, 0.0]
13 Pre-bronchodilator FEV ₁ (mL) at week 52	1		Mean Difference (Random, 95% CI)	Subtotals only
13.1 75 mg mepolizumab versus placebo	1	308	Mean Difference (Random, 95% CI)	61.00 [-37.00, 161.00]
13.2 250 mg mepolizumab versus placebo	1	307	Mean Difference (Random, 95% CI)	81.00 [-18.51, 180.51]
13.3 750 mg mepolizumab versus placebo	1	311	Mean Difference (Random, 95% CI)	56.0 [-41.00, 155.00]
14 Late asthmatic reaction (maximum % fall in FEV ₁)	1		Mean Difference (Random, 95% CI)	Subtotals only
14.1 2.5 mg/kg mepolizumab versus placebo	1	16	Mean Difference (Random, 95% CI)	3.50 [-3.46, 10.46]
14.2 7.5 mg/kg mepolizumab versus placebo	1	16	Mean Difference (Random, 95% CI)	0.3 [-6.50, 7.10]
15 Asthma symptoms	5		Mean Difference (Random, 95% CI)	Subtotals only
15.1 75 mg mepolizumab versus placebo	2	690	Mean Difference (Random, 95% CI)	-0.30 [-0.55, -0.04]
15.2 250 mg mepolizumab versus placebo	2	553	Mean Difference (Random, 95% CI)	-0.24 [-0.48, 0.01]
15.3 750 mg mepolizumab versus placebo	4	631	Mean Difference (Random, 95% CI)	-0.02 [-0.57, 0.54]
16 Asthma symptoms (JACQ)	2	80	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.42, 0.35]

Comparison 2. SC Mepolizumab versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Health-related quality of life	1		Mean Difference (Random, 95% CI)	Totals not selected
1.1 SGRQ	1		Mean Difference (Random, 95% CI)	0.0 [0.0, 0.0]
2 Rate of exacerbations requiring admission	1		Rate Ratio (Random, 95% CI)	Totals not selected
3 Rate of exacerbations requiring ED or admission	1		Rate Ratio (Random, 95% CI)	Totals not selected
4 Rate of clinically significant exacerbations	1		Rate Ratio (Random, 95% CI)	Totals not selected


5 Pre bronchodilator FEV ₁ (litres)	1	Mean Difference (Random, 95% CI)	Totals not selected
5.1 32 weeks	1	Mean Difference (Random, 95% CI)	0.0 [0.0, 0.0]
6 Post bronchodilator FEV ₁ (litres)	1	Mean Difference (Random, 95% CI)	Totals not selected
6.1 32 weeks	1	Mean Difference (Random, 95% CI)	0.0 [0.0, 0.0]
7 Asthma symptoms	1	Mean Difference (Random, 95% CI)	Totals not selected

Analysis 1.1. Comparison 1 IV Mepolizumab versus placebo, Outcome 1 Health-related quality of life (AQLQ).

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 1 Health-related quality of life (AQLQ)




Analysis 1.2. Comparison 1 IV Mepolizumab versus placebo, Outcome 2 Health-related quality of life (SGRQ).

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 2 Health-related quality of life (SGRQ)




Analysis 1.3. Comparison 1 IV Mepolizumab versus placebo, Outcome 3 Rate of clinically significant exacerbations.

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 3 Rate of clinically significant exacerbations




Analysis 1.4. Comparison 1 IV Mepolizumab versus placebo, Outcome 4 Rate of exacerbations requiring admission.

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 4 Rate of exacerbations requiring admission




Analysis 1.5. Comparison 1 IV Mepolizumab versus placebo, Outcome 5 Rate of exacerbations requiring ED or admission.

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 5 Rate of exacerbations requiring ED or admission




Analysis 1.6. Comparison 1 IV Mepolizumab versus placebo, Outcome 6 People with one or more exacerbations.

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 6 People with one or more exacerbations




Analysis 1.7. Comparison 1 IV Mepolizumab versus placebo, Outcome 7 Serious adverse events.

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 7 Serious adverse events




Analysis 1.8. Comparison 1 IV Mepolizumab versus placebo, Outcome 8 FEV1 (litres).

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 8 FEV1 (litres)




Analysis 1.9. Comparison 1 IV Mepolizumab versus placebo, Outcome 9 PEFR (L/min).

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 9 PEFR (L/min)




Analysis 1.10. Comparison 1 IV Mepolizumab versus placebo, Outcome 10 Post bronchodilator FEV₁ (L).

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 10 Post bronchodilator FEV₁ (L)




Analysis 1.11. Comparison 1 IV Mepolizumab versus placebo, Outcome 11 Percentage predicted FEV₁ after bronchodilation.

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 11 Percentage predicted FEV₁ after bronchodilation




Analysis 1.12. Comparison 1 IV Mepolizumab versus placebo, Outcome 12 Pre-bronchodilator FEV₁ (L) at week 32.

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 12 Pre-bronchodilator FEV₁ (L) at week 32




Analysis 1.13. Comparison 1 IV Mepolizumab versus placebo, Outcome 13 Pre-bronchodilator FEV₁ (mL) at week 52.

Review: Mepolizumab versus placebo for asthma


Comparison: 1 IV Mepolizumab versus placebo

Outcome: 13 Pre-bronchodilator FEV₁ (mL) at week 52



(Continued ...)

(... Continued)




Analysis 1.14. Comparison 1 IV Mepolizumab versus placebo, Outcome 14 Late asthmatic reaction (maximum % fall in FEV1).

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 14 Late asthmatic reaction (maximum % fall in FEV1)




Analysis 1.15. Comparison 1 IV Mepolizumab versus placebo, Outcome 15 Asthma symptoms.

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 15 Asthma symptoms




Analysis 1.16. Comparison 1 IV Mepolizumab versus placebo, Outcome 16 Asthma symptoms (JACQ).

Review: Mepolizumab versus placebo for asthma

Comparison: 1 IV Mepolizumab versus placebo

Outcome: 16 Asthma symptoms (JACQ)




Analysis 2.1. Comparison 2 SC Mepolizumab versus placebo, Outcome 1 Health-related quality of life.

Review: Mepolizumab versus placebo for asthma

Comparison: 2 SC Mepolizumab versus placebo

Outcome: 1 Health-related quality of life




Analysis 2.2. Comparison 2 SC Mepolizumab versus placebo, Outcome 2 Rate of exacerbations requiring admission.

Review: Mepolizumab versus placebo for asthma

Comparison: 2 SC Mepolizumab versus placebo

Outcome: 2 Rate of exacerbations requiring admission




Analysis 2.3. Comparison 2 SC Mepolizumab versus placebo, Outcome 3 Rate of exacerbations requiring ED or admission.

Review: Mepolizumab versus placebo for asthma

Comparison: 2 SC Mepolizumab versus placebo

Outcome: 3 Rate of exacerbations requiring ED or admission




Analysis 2.4. Comparison 2 SC Mepolizumab versus placebo, Outcome 4 Rate of clinically significant exacerbations.

Review: Mepolizumab versus placebo for asthma

Comparison: 2 SC Mepolizumab versus placebo

Outcome: 4 Rate of clinically significant exacerbations




Analysis 2.5. Comparison 2 SC Mepolizumab versus placebo, Outcome 5 Pre bronchodilator FEV1 (litres).

Review: Mepolizumab versus placebo for asthma

Comparison: 2 SC Mepolizumab versus placebo

Outcome: 5 Pre bronchodilator FEV₁ (litres)




Analysis 2.6. Comparison 2 SC Mepolizumab versus placebo, Outcome 6 Post bronchodilator FEV1 (litres).

Review: Mepolizumab versus placebo for asthma

Comparison: 2 SC Mepolizumab versus placebo

Outcome: 6 Post bronchodilator FEV₁ (litres)




Analysis 2.7. Comparison 2 SC Mepolizumab versus placebo, Outcome 7 Asthma symptoms.

Review: Mepolizumab versus placebo for asthma

Comparison: 2 SC Mepolizumab versus placebo

Outcome: 7 Asthma symptoms



ADDITIONAL TABLES

Table 1. Comparisons of study characteristics

Study	Design	Base-line Asthma severity	Baseline treatment	SC or IV	Intervention (mepolizumal)	Follow-up	Primary and secondary outcomes	No. participants
Leckie 2000	RCT double-blind, placebo	Mild allergic asthma	SABA as required	IV	10 mg/kg versus 2.5 mg/kg versus placebo	16 weeks	Blood eosinophils, sputum eosinophils, histamine PC ₂₀ (mg/mL), late asthmatic reaction (maximum % fall in FEV ₁)	24
Buttner 2003	RCT parallel group, multicentre double blind	Mild or moderate asthma (FEV ₁ 50-80% predicted)	1000 mcg BDP or equivalent and stable	IV	Three 750 or 250 mg or placebo every 4 weeks for 6 months	6 months	Blood eosinophil, ECP, interferon- γ producing CD4 T-cells	19
Flood-Page 2003	2-centre double-blind, placebo-controlled, parallel-group study	Mild atopic (skin prick positive) asthma (FEV ₁ >70% predicted)	SABA as required and no corticosteroids in previous 8 weeks	IV	Three doses of either 750 mg or placebo over 20 weeks (at weeks 0, 4 and 8)	20 weeks	Airway eosinophils, bone marrow eosinophils, blood eosinophils, airway hyperresponsiveness, FEV ₁ , PEFr	24
Flood-Page 2007	Multicentre, randomised, double-blind, placebo-controlled trial	Moderate asthma (FEV ₁ between 50% and 80% predicted)	maximum dose (BDP) or equivalent, 1000 mcg/d	IV	Three doses of either 750 mg or 250 mg or placebo over 20 weeks (at weeks 0, 4 and 8)	20 weeks	Change from base-line morning PEFr recorded at weeks 12 and 20; asthma summary symptom scores; use of	362

Table 1. Comparisons of study characteristics (Continued)

							rescue medication such as albuterol (salbutamol); quality of life scores; asthma exacerbation rates; eosinophil counts in blood and sputum	
Nair 2009	Randomised, double-blind, placebo-controlled trial.	Eosinophilic asthma	Prednisolone treatment with high-dose ICS	IV	Five doses of either 750 mg or placebo (administered in 5 monthly infusions)	26 weeks	Juniper ACQ in patients with asthma or by Likert symptom scores + FEV ₁ in patients with eosinophilic bronchitis without asthma); the prednisone-sparing effect of mepolizumab or placebo as indicated by the absolute and percentage dose reduction possible without a clinical exacerbation (defined as % sputum eosinophilia, FEV ₁ % predicted	20

Table 1. Comparisons of study characteristics (Continued)

							and methacholine PC ₂₀); blood eosinophils; frequency of rescue salbutamol use; time to exacerbation	
Haldar 2009	RCT double-blind, placebo, parallel-group	Eosinophilic asthma and exacerbations	Sputum eosinophilia of more than 3% despite high-dose ICS treatment, and at least two exacerbations in previous 12 months	IV	750 mg versus matched placebo (150 mL of 0.9% saline) at monthly intervals for 1 year	50 weeks	Severe exacerbations per person; secondary outcomes included a change in asthma symptoms (AQLQ); FEV ₁ after use of a bronchodilator; airway hyperresponsiveness; eosinophil counts in the blood, sputum	61
Pavord 2012	Multi-centre, double-blind, placebo-controlled trial	Eosinophilic asthma and exacerbations	High dose ICS (i.e. ≥ 880 mcg/day FP or equivalent daily) for at least 12 months	IV	13 infusions in total given every 4 weeks of 750 mg, 250 mg, 75 mg or placebo	52 weeks	Exacerbations; time to first clinically significant exacerbation; frequency of exacerbations requiring hospitalisation; time to first exacerbation requiring hospitalisation or ED visit; mean change	621

Table 1. Comparisons of study characteristics (Continued)

								from baseline in clinic pre-bronchodilator FEV ₁ ; mean change from baseline in clinic post-bronchodilator FEV ₁ ; mean change from baseline in ACQ score	
Ortega 2014	Randomised, double-blind, double-dummy, phase 3 study	Persistent eosinophilic asthma	High dose ICS in the 12 months prior to visit 1 with or without maintenance OCS	IV and SC	75 mg IV dose versus 100 mg SC dose versus placebo every 4 weeks for 32 weeks	32		Exacerbations per year; mean change from baseline in clinic pre-bronchodilator FEV ₁ at week 32; mean change from baseline in the SGRQ total score at week 32	576

ACQ: Asthma Control Questionnaire; **AQLQ:** Asthma Quality of Life Questionnaire; **BDP:** beclomethasone dipropionate; **ECP:** eosinophil cationic protein; **ED:** emergency department; **FEV₁:** Forced expiratory volume in 1 second; **FP:** fluticasone propionate; **ICS:** inhaled corticosteroid; **IV:** intravenous; **PC₂₀:** histamine provocative concentration causing a 20% drop in FEV₁; **PEFR:** peak expiratory flow rate; **RCT:** randomised controlled trial; **SABA:** short-acting beta-agonists; **SC:** subcutaneous; **SGRQ:** St George's Respiratory Questionnaire.

Table 2. Lung function

Study	Outcome	Intervention			Control			Median difference	P value (between groups)
		N	Pre-dose median (IQR)	Post-dose median (IQR)	N	Pre-dose median (IQR)	Post-dose median (IQR)		
Flood-Page 2003	FEV ₁ L/s	11	3.05 (2.69 to 3.28)	3.1 (2.82 to 3.85)	13	3.1 (2.65 to 3.51)	3.06 (2.65 to 3.45)	0.15	0.22

Table 2. Lung function (Continued)

Flood- Page 2003	Morn- ing PEFR L/min	11	433 (402 to 497)	436 (417 to 503)	12	459.5 (408 to 481)	448 (370 to 490)	21	0.09
---------------------	----------------------------	----	---------------------------	---------------------------	----	-----------------------------	---------------------------	----	------

FEV₁ : Forced expiratory volume in 1 second; IQR: interquartile range; PEFR: peak expiratory flow rate

Table 3. Eosinophils from Flood-Page 2003

Outcome	Intervention			Control			P value
	N	Pre-dose median (IQR)	Post-dose median (IQR)	N	Pre-dose median (IQR)	Post-dose median (IQR)	
BALF (% cell type on cy- tospin) Eosinophils	11	1.4 (0.9 to 10.2)	0.3 (0.01 to 0.8)	13	1.2 (0.2 to 6)	1.2 (0.3 to 1.6)	0.4

BALF: bronchoalveolar lavage fluid; IQR: interquartile range

Table 4. Eosinophils from Haldar 2009

Outcome	Intervention		Control		P value
	N	Percentage	N	Percentage	
Ge- ometric mean spu- tum eosinophil % during exacerbation	29	1.5%	32	4.4%	0.005
Sputum eosinophil count >3% during exacerbation (% of episodes)	29	36%	32	59%	0.04

Table 5. Sputum eosinophil results from Leckie 2000

Outcome	Day	Intervention Mepolizumab (10 mg/kg) N=8	Intervention Mepolizumab (2.5 mg/kg) N=7
		Difference (95%CI)	Difference

Table 5. Sputum eosinophil results from Leckie 2000 (Continued)

Difference in blood eosinophils vs placebo pre-allergen	Day - 14	0.08 (- 0.09 to 0.26), P = 0.4960	0.18 (0.01 to 0.36), P = 0.0292
	Day 8	0.17 (0.04 to 0.30), P = 0.0054	0.01 (- 0.16 to 0.19), P = 1.00
	Day 29	0.21 (0.10 to 0.33), P < 0.0001	0.02 (- 0.14 to 0.18), P = 1.00
Difference in blood eosinophils vs placebo post-allergen	Day - 13	0.38 (0.07 to 0.69), P = 0.0144	0.23 (- 0.11 to 0.58), P = 0.2136
	Day 9	0.34 (0.13 to 0.55), P = 0.0006	0.32 (0.11 to 0.53), P = 0.0012
	Day 30	0.49 (0.28 to 0.7), P < 0.0001	0.43 (0.22 to 0.65), P = 0.0002
Difference in sputum eosinophils vs placebo	Day -13	- 2.0 (- 16.2 to 12.3), P = 1.00	- 2.1 (- 16.3 to 12.2), P = 1.00
	Day 9	11.3 (2.6 to 20.1), P = 0.0076	5.0 (- 5.9 to 16.0), P = 0.6108
	Day 30	12.1 (3.1 to - 21.0), P = 0.0050	5.9 (- 5.0 to 16.8), P = 0.4454

Table 6. Sputum eosinophil results from Nair 2009

Outcome	Visit	Intervention		Control		P value
		N	median (range)	N	median (range)	
Spu- tum eosinophils (%) median	Visit 1	9	16.6 (1.6 to 54.3)	11	4.0 (0 to 35.3)	P < 0.05 compared to base- line
	4 weeks after first dose	9	0 (range 0 to 4.0)	10	3.0 (0 to 16.3)	P < 0.05 compared to base- line
			mean (SD)		mean (SD)	
Blood eosinophils (x 10 ⁹ /L)	Visit 1	9	664.4 (492.5)	11	352.1 (± 253.7)	P < 0.05 compared to base- line
	4 weeks after first dose	9	49.5 (37.5)	10	295.8 (± 207.4)	P < 0.05 compared to base- line

APPENDICES

Appendix I. Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)

Electronic searches: core databases

Database	Frequency of search
CENTRAL (<i>the Cochrane Library</i>)	Monthly
MEDLINE (Ovid)	Weekly
EMBASE (Ovid)	Weekly
PsycINFO (Ovid)	Monthly
CINAHL (EBSCO)	Monthly
AMED (EBSCO)	Monthly

Hand-searches: core respiratory conference abstracts

Conference	Years searched
American Academy of Allergy, Asthma and Immunology (AAAAI)	2001 onwards
American Thoracic Society (ATS)	2001 onwards
Asia Pacific Society of Respiriology (APSR)	2004 onwards
British Thoracic Society Winter Meeting (BTS)	2000 onwards
Chest Meeting	2003 onwards
European Respiratory Society (ERS)	1992, 1994, 2000 onwards
International Primary Care Respiratory Group Congress (IPCRG)	2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ)	1999 onwards

MEDLINE search strategy used to identify trials for the CAGR

Asthma search

1. exp Asthma/
2. asthma\$.mp.
3. (antiasthma\$ or anti-asthma\$).mp.
4. Respiratory Sounds/
5. wheez\$.mp.
6. Bronchial Spasm/
7. bronchospas\$.mp.
8. (bronch\$ adj3 spasm\$).mp.
9. bronchoconstrict\$.mp.
10. exp Bronchoconstriction/
11. (bronch\$ adj3 constrict\$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial\$ or respiratory or airway\$ or lung\$) adj3 (hypersensitiv\$ or hyperreactiv\$ or allerg\$ or insufficiency)).mp.
15. ((dust or mite\$) adj3 (allerg\$ or hypersensitiv\$)).mp.
16. or/1-15

Filter to identify RCTs

1. exp "clinical trial [publication type]"/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11

The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.

Appendix 2. Search Strategy for Cochrane Airways Group Register

- #1 AST:MISC1
- #2 MeSH DESCRIPTOR Asthma Explode All
- #3 asthma*:ti,ab
- #4 #1 or #2 or #3
- #5 MeSH DESCRIPTOR Antibodies, Monoclonal
- #6 MeSH DESCRIPTOR Antibodies, Monoclonal, Humanized
- #7 mepolizumab*
- #8 SB24056 or SB-24056
- #9 human* NEAR2 monoclonal* NEAR2 antibod*
- #10 Bosatria
- #11 #5 or #6 or #7 or #8 or #9 or #10
- #12 #4 and #11

[In search line #1, MISC1 denotes the field where the reference has been coded for condition, in this case, asthma]

CONTRIBUTIONS OF AUTHORS

SM, KD, NW and CP contributed to the writing of the protocol. NW and CP independently selected trials for the review, NW and LB extracted the data, and KD entered the data into the [RevMan](#) file with cross-checking by SM. KD and SM wrote the Results section, and NW, LB, CP, KD and SM coauthored the Discussion and Conclusions.

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

- No sources of support supplied

External sources

- National Institute for Health Research (SJM), UK.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We initially planned to use a fixed-effect model for meta-analysis, but we agreed with a peer reviewer who suggested that a random-effects model was more appropriate in view of the substantial clinical heterogeneity between the trials.

Although sufficient studies were not identified to conduct subgroup analyses, a posthoc subgroup analysis of dose of intervention was identified and included for use in a future version of this review.

We have included lung function and asthma symptoms in the summary of findings table as additional outcomes which we believe to be important to people making decisions about this intervention.

INDEX TERMS

Medical Subject Headings (MeSH)

Antibodies, Monoclonal, Humanized [*administration & dosage]; Asthma [*therapy]; Disease Progression; Injections, Intravenous; Injections, Subcutaneous; Quality of Life

MeSH check words

Adolescent; Adult; Child; Humans